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Vici syndrome is a rare autosomal recessive inherited multisystem disorder caused by 
mutations in EPG5. More than 80% of the patients with Vici syndrome suffer from 
cardiomyopathy. In this study, the induced pluripotent stem cell (iPSC) system was 
applied to model the disease, investigate the cardiac phenotype and to elucidate the 
underlying molecular mechanism of autophagy in cardiomyocytes derived from iPSCs. 
HiPSCs from the patient with Vici syndrome (Vici-iPSCs) carrying a homologous 
intronic mutation of EPG5 (c.4952+1G>A) were generated. These Vici-iPSC lines were 
pluripotent and could be differentiated into functional cardiomyocytes. Analysis of 
sarcomeric structure of cardiomyocytes derived from Vici-iPSCs (Vici-iPSC-CMs) 
showed they possessed a larger cell surface area with a higher inhomogeneity of 
sarcomere length compared with the cardiomyocytes derived from the Ctr-iPSCs 
(Ctr-iPSC-CMs). Furthermore, analysis of autophagy-related marker LC3 and lysosome 
associated protein 1 (LAMP1) demonstrated numerous accumulation of autophagosomes, 
abnormal perinuclear localization of lysosomes as well as the fusion blockade of 
autophagosomes with lysosomes in Vici-iPSC-CMs. Further investigation of the 
regulatory pathway of autophagy showed that the level of AKT phosphorylation at two 
activating sites (serine 473 and threonine 308) was decreased in Vici-iPSC-CMs 
compared to Ctr-iPSC-CMs. In addition, to figure out if these phenotypes in 
Vici-iPSC-CMs are caused by the EPG5 mutation, the genomic editing tool 
CRISPR/Cas9 was used to rescue the mutation site in EPG5. After transduction of 
CRISPR/Cas9-GFP and single-stranded oligonucleotides, genotype analysis of the 150 
surviving Vici-iPSC colonies illustrated that non-homologous end joining (NHEJ) 
happens to repair the DNA double-strand break in two iPSC colonies. However, the 
mutation site in EPG5 was not rectified in any Vici-iPSC colonies. The data of this study 
illustrate that patient-specific iPSCs can be used to model Vici syndrome associated 





1.1 Stem cells and cellular reprogramming 
1.1.1 Definition and characteristics of stem cells 
Stem cells are undifferentiated cells, which possess the capacity to differentiate into 
specialized cells and to self-renew. Depending on their origin, stem cells are divided into 
two types: embryonic stem cells (ESCs) and adult stem cells. ESCs derived from the 
inner cell mass of an early blastocyst are pluripotent and have the capacity to develop 
into all derivatives of three embryonic germ layers and germ cells. Adult stem cells 
originated in different tissues are multipotent or unipotent and only capable of generating 
its committed cell types.  
 
The self-renewal and differentiation potential of stem cells make them useful for studying 
embryogenesis and genetic diseases. Martin Evans firstly isolated mouse embryonic stem 
cells (mESCs) in 1981 and subsequent studies further established that leukemia inhibitor 
factor was essential for the long-term cultures of mESCs to maintain them in an 
undifferentiated state (Evans and Kaufman, 1981; Smith et al., 1988). The difficulty to 
obtain the human blastocyst impedes the isolation of human embryonic stem cells 
(hESCs) in vitro. HESCs were first isolated in 1994 (Bongso et al., 1994) and 
subsequently, cell lines were established when the cells were cultured on inactivated 
mouse embryonic fibroblasts (MEFs) as a feeder layer in medium containing basic 
fibroblast growth factors (bFGFs) (Bongso et al., 1994; Thomson et al., 1998). The 
traditional feeder layer culture of hESCs is time-consuming due to the necessity of 
inactivated MEFs as well as the bias towards differentiated cells in long-term cultures. To 
avoid this, advancement in cell attachment and cell culture conditions for hESCs with 
chemical defined medium were pursued, for example, mTeSR and Essential 8 (E-8) 
medium combined with a gelatinous protein mixture such as Matrigel and Geltrex (Chen 
et al., 2011; Vallier, 2011). These improvements, feeder- and serum-free culture 
conditions, lead to controllable and reproducible conditions for growth and amplification 
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of hESCs, which make the use of hESCs feasible for studying embryogenesis and 
modeling disease. 
 
Furthermore, the unique properties of self-renewal and differentiation possessed by 
hESCs have great prospects for regenerative medicine. However, the supply and the 
destruction of blastocysts for the generation of hESCs are medically and ethically 
controversial, thus limit the use of these cells in disease treatments (Solter, 2006). The 
breakthrough in the discovery of human induced pluripotent stem cells (hiPSCs) by 
Shinya Yamanaka (Takahashi et al., 2007), which were generated from human fibroblasts 
derived from skin biopsy, circumvented the medical and ethical dilemma associated with 
hESCs. As a result, hiPSCs become widely available to research groups, allowing these 
cells to be exploited for disease modeling, drug discovery and potential cell replacement 
therapeutics.  
1.1.2 Cellular and lineage reprogramming 
Embryogenesis is a naturally and uni-directionally occurring process where a fertilized 
egg develops into specialized somatic or germ cells. Upon exposure to growth factors and 
resulting signaling cues, the cells become committed in their fates and are believed to be 
irreversible. However, the concept of reversing cell fate is verified by cellular 
reprogramming and lineage reprogramming, which includes the conversion of 
differentiated somatic cells back to an embryonic state and the transdifferentiation of one 
specialized cell type into another.  
 
Cell reprogramming was first demonstrated by using somatic cell nuclear transfer 
technology in frogs where the nucleus from a differentiated cell was injected into an 
unfertilized and enucleated egg resulting in viable tadpoles (Gurdon, 1962). Three 
decades later, Ian Wilmut cloned “Dolly” the sheep and demonstrated for the first time 
that mammalian epithelial cells could be reverted back to pluripotent cells through 
cellular reprogramming (Wilmut et al., 1997). Later, other mammalian animals had been 
successfully cloned (Hochedlinger and Jaenisch, 2002; Wakayama and Yanagimachi, 
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1999). Inducing pluripotency was further confirmed by fusing adult thymocytes with 
ESCs (Tada et al., 2001). These studies suggest that a set of unknown factors in oocytes 
and ESCs are responsible for the interplay of pluripotency and somatic state in cells.  
 
In 2006, these factors that allowed nuclear reprogramming were discovered. The research 
group led by Prof. Yamanaka successfully reprogrammed mouse somatic cells into the 
pluripotent state by using the retroviral delivery of four key genes; oct3/4 (octamer 
binding transcription factor 3/4), sox2 (SRY-box 2), klf4 (Krüppel-like factor 4), and 
c-myc (Takahashi and Yamanaka, 2006). They initially screened 24 candidates that were 
highly expressed in ESCs for pluripotency and made a series of different combinations to 
transduce MEFs. Finally, the master transcription factors oct3/4, sox2, klf4 and c-myc 
were deemed to fulfill the induction of pluripotency from somatic cells. These 
reprogrammed cells were termed induced pluripotent stem cells (iPSCs) and 
demonstrated similar features of ESCs including morphology, growth properties and 
expression of ESC markers.  
 
The similar approach was subsequently used to generate iPSCs from human, monkey, pig, 
dog and rat (Esteban et al., 2009; Honda et al., 2010; Li et al., 2009; Liao et al., 2009; Liu 
et al., 2008; Shimada et al., 2010; Takahashi et al., 2007; Yu et al., 2007). Additionally, 
the different types of somatic cells were successfully reprogrammed into iPSCs and fewer 
transcription factors were subsequently found to sufficiently induce pluripotency in some 
cell types, such as adult neural stem cells, in which OCT4 alone was sufficient to achieve 
pluripotency (Kim et al., 2009b). The iPSCs avoid the ethical concerns associated with 
hESCs and provide researchers potentially the unlimited supply of pluripotent stem cells 
for studying molecular mechanisms of diseases and their application in regenerative 
medicine.  
 
However, retroviral-mediated transduction may cause random integration of transgenes 
and potential oncogenes into the host cell genome, which could lead to undesirable 
effects such as tumor formation. Further relatively “safer” approaches of generating 
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integration-free iPSCs were developed. These approaches allowed the delivery of the 
genes using other platforms such as plasmid transfection, adenovirus, Sendai virus, 
proteins, RNAs and small molecules (Fusaki et al., 2009; Hou et al., 2013; Kim et al., 
2009a; Kim et al., 2011; Loh et al., 2009; Okita et al., 2011; Okita et al., 2008; Stadtfeld 
et al., 2008; Warren et al., 2010). The generation of iPSCs is a process with a low 
efficiency, typically less than 1% of transfected or transduced cells become iPSCs. 
Pluripotency induction with combined proteins was proved to be more challenging with 
even lower efficiency. The plasmid transfection and Sendai virus transduction are now 
routinely used in many laboratories due to their simplicity and reproducibility (Yamanaka, 
2012).  
 
Furthermore, transdifferentiation (lineage reprogramming) where one specialized cell 
type directly converts into another was accomplished through ectopic expression of the 
master transcription factors specific for the cell lineage. In 1987, Davis reported that 
MEFs were able to be converted into myoblasts through myod overexpression (Davis et 
al., 1987). Recently, fibroblasts were successfully reprogrammed into functional 
cardiomyocytes from different species by overexpression of a set of cardiac-specific key 
factors, such as GATA4, MEF2C, and TBX5 (Cao et al., 2016; Ieda et al., 2010; 
Jayawardena et al., 2012; Qian et al., 2012; Song et al., 2012). Direct conversion of 
mouse fibroblasts to functional neurons was fulfilled by the defined factors and small 
molecules, such as brn2 (also known as pou3f2), ascl1 and myt1l (Pang et al., 2011; 
Vierbuchen et al., 2010; Xue et al., 2013).  
1.2 Vici syndrome 
1.2.1 Definition of Vici syndrome 
Vici syndrome is a multisystem disorder characterized by five key pathological features: 
callosal agenesis, cataracts, cardiomyopathy, hypopigmentation and combined 
immunodeficiency (Dionisi Vici et al., 1988). Apart from these five principal diagnostic 
findings, a wide range of variably present additional features has been reported (Cullup et 
al., 2013; Byrne et al., 2016a). Vici syndrome is a rare autosomal recessive inherited 
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disease caused by mutations in EPG5 (ectopic P-granules autophagy protein 5) that 
locates on chromosomal 18q12.3 (Cullup et al., 2013). Until now, there have been at least 
50 cases of Vici syndrome reported worldwide. Besides the classical clinical features 
reported, renal tubular acidosis, neuromuscular involvement, sensorineural hearing loss 
and sleep abnormalities can develop into other clinical complications in patients suffering 
from this syndrome (Al-Owain et al., 2010; Chiyonobu et al., 2002; del Campo et al., 
1999; Ehmke et al., 2014; El-Kersh et al., 2015; Filloux et al., 2014; Finocchi et al., 2012; 
Huenerberg et al., 2016; Lu et al., 2016; McClelland et al., 2010; Miyata et al., 2014; 
Miyata et al., 2007; Ozkale et al., 2012; Rogers et al., 2011; Said et al., 2012; Tasdemir et 
al., 2016).  
 
The frequency of clinical features was evaluated depending on the 38 genetically 
confirmed cases (Byrne et al., 2016a). All of these patients exhibit an absence of corpus 
callosum, gross development delay and immunological deficiencies. 97% of the patients 
are with median survival around 42 months (range 1 to 102 months). Additionally, most 
patients exhibit a pale complexion and light hair; 90% of the patients acquire 
microcephaly; 82% of the patients suffer from cardiomyopathy; 76% develop cataracts. 
Furthermore, additional dysfunctions of other organs including thymus, lungs, thyroid, 
liver, kidney and blood in most patients are also observed. Hence, despite Vici syndrome 
being a rare disease, its existence can result in multiple disorders and the mechanism of 
disease progression remains to be elucidated. 
1.2.2 Myopathy and cardiomyopathy in Vici syndrome  
Patients with Vici syndrome exhibit defective skeletal muscle and cardiomyocytes. The 
marked hypotonia, weak movement and delayed motor neuron development in patients 
with Vici syndrome reflect skeletal myopathy. Studies using skeletal muscle biopsy from 
the patients revealed variable myofibril size, centralized nuclei, hypotrophic fibers and 
accumulated glycogen (Al-Owain et al., 2010; McClelland et al., 2010). Disorganized 
sarcomeres, abnormal localization of mitochondria (ring-shape) and large autophagy 
vesicles were also observed.  
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Notably, majority (around 80%) of affected children exhibited hypertrophic or dilated 
cardiomyopathy especially in the left ventricle. In addition, 10% of patients were reported 
to have minor congenital heart defects including open patent foramen ovale, ventricular 
or atrial septal defects, hypoplastic aortic arch or mitral valve insufficiency (Byrne et al., 
2016a). Histo-pathological analysis of the heart tissue revealed that vacuoles and 
membrane bound cytoplasmic inclusions existed in cardiomyocytes (Miyata et al., 2014). 
The cardiomyocytes also showed increased staining for autophagy markers LC3 
(microtubule-associated protein 1 light chain 3) and P62 on immunohistochemistry. 
While cardiomyopathy is usually detected in early life of patients with Vici syndrome, 
intermittent deterioration of cardiac function can occur during the progression of the 
disease in the later stages further complicated by failure of respiratory system and heart 
function. The cardiomyopathy in patients with Vici syndrome suggests that autophagy 
has an important function in the human heart, which requires further investigation using 
appropriate models.  
1.3 Autophagy  
Autophagy plays a key role in removing damaged proteins and deteriorated organelles 
and in supplying cellular energy and nutrients (Kaur and Debnath, 2015). Autophagy is a 
conserved catabolic process with the capacity to degrade long-lived proteins and 
organelles such as aggregated proteins, mitochondria, ribosomes and peroxisomes. In 
contrast to autophagy, the ubiquitin-proteasome system (UPS) is the other key 
mechanism of maintaining the protein hemostasis, which targets the short-lived proteins 
(Hershko and Ciechanover, 1998; Shaid et al., 2013). 
 
Autophagy can be divided into three types, including the macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA). Macroautophagy, 
generically known as autophagy, is the main pathway involving the formation of 
autophagosomes and autolysosomes to degrade the proteins. Microautophagy is the 
process where cytoplasmic degraded components are directly engulfed by lysosomes with 
the process of invagination of the lysosomal or endosomal membrane (Li et al., 2012). 
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CMA differs from macroautophagy and microautophagy because degraded proteins are 
translocated without membrane invagination. Proteins that contain a KFERQ 
(lysine-phenylalanine-glutamic acid-arginine-glutamine) motif are recognized by the 
chaperone heat shock cognate 70 kDa protein (HSC70), which could bind to lysosome 
associated membrane protein 2A (LAMP2A). By this way, the substrate proteins  cross 
the lysosomal membrane for subsequent degradation (Cuervo and Wong, 2014) (Figure 
1A). 
 
Figure 1. Introduction of autophagy process. A, Autophagy is classified into three types. 
Macroautophagy is a stepwise process that involves the following: 1) initiation and isolation of 
membrane, phagophores; 2) nucleation of phagophores; 3) elongation and maturation of 
phagophores into autophagosomes; 4) autophagosomes fusing with lysosomes, called 
autolysosomes; 5) degradation in the lysosomes. This intricate process is regulated by different 
complex. The phagophores assembly site (PAS) is mediated by the UNC51-like kinase (ULK) 
complex, which contains ULK1, autophagy related protein 13 (ATG13), FAK family kinase 
interacting protein of 200 kDa (FIP200) and ATG101. The nucleation of phagophores is regulated 
by the class III PI3K complex, which consists of beclin1, ATG14L, vacuolar protein sorting 15 
(VPS15) and VPS34. The elongation and maturation of phagophores is controlled by a complex, 
which is composed of ATG5, ATG12, ATG16L and PE-LC3. Chaperone mediated autophagy 
(CMA) requires heat shock cognate 70 kDa protein (HSC70) that can recognize the 
KFERQ-motif-containing degraded proteins, which are translocated into lysosomes with binding 
of HSC70 to lysosome associated membrane protein 2A (LAMP2A). Microautophagy engulfs the 
proteins directly with the invagination of lysosomal or endosomal membranes. B, The selective 
autophagy of degraded organelles such as mitochondria, pathogens, ribosomes, peroxisomes, 
endoplasmic reticulum and aggregated proteins is mediated by autophagy adaptors including P62 





Autophagy was initially thought to be a process attributed to nutrient starvation (induced 
autophagy), which represents non-selective degradation of cytoplasmic components (De 
Duve et al., 1955; De Duve and Wattiaux, 1966). However, this was later observed to be a 
selective process, in which the partially degraded aggregated proteins and organelles are 
selectively sequestered into autophagosomes (Bjorkoy et al., 2005; Kirkin et al., 2009a). 
Based on the substrate, selective autophagy was separated into mitophagy (mitochondria), 
xenophagy (pathogens), ribophagy (ribosomes), pexophagy (peroxisomes) and 
reticulophagy (endoplamatic) (Shaid et al., 2013). The recognition of selective degraded 
targets involves the ubiquitin binding proteins, such as P62/SQSTM1 and NBR1 (next to 
BRCA1 gene 1). P62 and NBR1 are autophagy adaptors, containing the ubiquitin-binding 
domain (UBD) and LC3-interacting region (LIR), which form a link between the 
degraded components and the autophagosomes (Kirkin et al., 2009b) (Figure 1B). LC3 is 
the most widely used autophagic marker that goes through a complex translational 
modifications. After synthesis of LC3, LC3I that located in the cytosol is immediately 
generated by cleaving the carboxyl terminal region of LC3 while conjugating to 
phosphatidylethanolamine (PE) of LC3I results in LC3II, which is located in the 
autophagosomal membrane. The conversion between LC3II and LC3I suggests the 
autophagic activity. With the function of LC3, P62 and NBR1, they act as autophagy 
markers to indicate dynamics of autophagy. 
1.3.1 Autophagy defects in diseases 
Autophagy can prevent the proteins and organelles from accumulating, on the other hand, 
the metabolites derived from proteins, lipids, ferritin and glycogen are recycled for 
diverse anabolisms including the protein, lipid and glycogen synthesis (Kaur and Debnath, 
2015). The importance of autophagy was confirmed by knocking out essential autophagy 
related genes, such as atg4, atg5, atg6 and atg7 (Kuma et al., 2004; Marino et al., 2007; 
Pua et al., 2007; Qu et al., 2007; Tanaka et al., 2000). Autophagy-defective oocytes 
derived from the oocyte-specific atg5 knockout mouse failed to develop beyond the four- 
and eight-cell stages when they were fertilized with atg5-null sperm (Tsukamoto et al., 
2008). The liver-specific atg7 knockout mouse showed protein aggregates, aberrant 
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mitochondrial structure and reduced removal of peroxisomes (Iwata et al., 2006). The 
atg7-null mouse was only able to survive 1 day after birth due to the lack of nutrients and 
energy (Komatsu et al., 2005).  
 
Autophagy dysfunction was also observed in the biopsies of muscles, liver, immune 
system and other organs, which were derived from various human diseases such as cancer 
and neurodegeneration diseases (Ezaki et al., 2011; Karantza-Wadsworth et al., 2007; 
Levine and Kroemer, 2008; Tannous et al., 2008). Autophagy deficiency in Alzheimer 
disease was shown by the accumulation of autophagic vacuoles in the affected neurons 
and reduced BECLIN1 expression in the brain tissue, which regulates the autophagosome 
formation (Nixon et al., 2005; Pickford et al., 2008; Small et al., 2005). In addition, the 
missense point mutation was identified in autophagy receptor gene P62/SQSTM1 in some 
patients with amyotrophie lateral sclerosis (ALS) (Hirano et al., 2013; Teyssou et al., 
2013). The β-propeller protein–associated neurodegeneration (BPAN) led to the reduced 
autophagic activity because of mutations in WDR45/WIPI14, a core autophagy gene 
(Haack et al., 2012; Saitsu et al., 2013). Autophagy is also involved in the tumorigenesis, 
in which autophagy as a candidate of tumor suppressor was discovered in 1999 (Liang et 
al., 1999). Decreased expression of autophagy gene BECLIN1 in human breast, ovarian 
and brain tumors and inhibited growth of cancer cells by ectopic expression of BECLIN1 
in tumor cell lines in vitro illustrated the important role of autophagy in suppressing 
tumor generation (Liang et al., 1999).  
 
Autophagy defects such as failure of autophagosomes fusing with lysosomes or the 
aggregation of proteins that exceed the capacity of autophagosome clearance has been 
linked to the pathogenesis of muscle diseases (Levine and Kroemer, 2008). 
Autophagosomes are abnormally accumulated in cardiac biopsies from patients with 
coronary artery disease, hypertension, aortic valvular disease and congestive heart failure 
(Terman and Brunk, 2005). As cardiac remodeling is a chronic maladaptive process, 
characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and 
deterioration of cardiac performance (Nishida and Otsu, 2015), the dynamic autophagy in 
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human heart is hard to observe due to the difficulty in obtaining human heart tissue. To 
elucidate the function of autophagy in the heart, mouse models are widely used to study 
the events involving the heart disease, which replicate specific disease situations of 
myocardial infarction (MI) and heart failure by ligation of a coronary artery or transverse 
aortic constriction (TAC). Evidence of relationship between autophagy and 
cardiomyopathy was demonstrated by specifically removing atg5 in cardiomyocytes in 
the adult mouse with phenotypic severe heart failure, observed by ventricular dilation, 
contractility dysfunction, irregular sarcomeres, aberrant mitochondrial structure and 
abnormal calcium transient after enhanced susceptibility to acute pressure overload 
(Kitsis et al., 2007; Nakai et al., 2007). In the pressure overload mouse model, autophagy 
activity was reduced following TAC induced hypertrophy, but increased during heart 
failure (Nishida et al., 2009). In the MI mouse model, autophagy was activated during the 
sub-acute and chronic stages after coronary occlusion (Kanamori et al., 2011). The 
dynamic autophagy during cardiac remodeling in the mouse models suggests that 
autophagy is protective to remove the excessive toxic proteins and damaged organelles 
but not sufficient against the deteriorate progression.      
1.3.2 Regulation of autophagy pathways  
Autophagy plays a key role in cell homeostasis for removing the damaged proteins and 
organelles, which is governed by multiple signal pathways. The mammalian target of 
rapamycin (mTOR), which regulates cell growth, proliferation, differentiation and 
survival, tumor cell motility, gene transcription and protein synthesis, is the most 
important protein for the autophagy control (Neufeld, 2010). The mTOR pathway 
involves the mTOR complex 1 (mTORC1) and the mTOR complex 2 (mTORC2). The 
phosphoinositide 3-kinase (PI3K) pathway is the major signaling cascade controlling 
mTOC1 and regulating autophagy (Figure 2). Briefly, growth factors such as insulin-like 
growth factor-1/2 (IGF1/2) and insulin bind to insulin receptors (IR) and activate PI3K 
via insulin receptor substrate (IRS). Activated PI3K converts PIP2 (phosphatidylinositol 
(4,5)-bisphosphate) to PIP3 (phosphatidylinositol (3,4,5)-trisphosphate), which recruits 
PDK1 and AKT to the plasma membrane and AKT is phosphorylated and activated, 
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which in turn phosphorylates and inactivates tuberous sclerosis complex (TSC) 1/2. The 
upstream regulator of mTORC1 is RHEB (Ras homolog enriched in brain), which 
directly activates mTORC1 expression. RHEB is inhibited by TSC1/2 (Boya et al., 2013), 
whose activity is negatively regulated by AKT.  
 
 
Figure 2. Schematic representation of mTOR-dependent autophagy regulation. Growth 
factors or insulin bind to insulin receptors (IR) and activate PI3K (phosphatidylinositol 3-kinase) 
via insulin receptor substrate (IRS). PI3K converts PIP2 to PIP3, which recruits PDK1 and AKT 
to the plasma membrane and AKT is phosphorylated and activated, which in turn phosphorylates 
and inactivates TSC1/2 complex. Inactivated TSC1/2 leads to activation of RHEB and 
consequently mTORC1 for autophagy inhibition. AMPK and GSK3 phosphorylate TSC1/2 
complex and result in mTORC1 inactivation to induce autophagy. Amino acids such as glutamine 
activate mTORC1 via Rag GTPase, which inhibits ULK1-Atg13-FIP200 complex and suppress 
autophagy. The mTORC1 consists of mTOR, the regulatory-associated protein of mTOR (Raptor) 
and mammalian lethal with SEC13 protein 8 (MLCST8), is rapamycin sensitive and regulates 
gene transcription, protein translation and autophagy. The mTORC2 consists of mTOR, 
rapamycin-insensitive companion of mTOR (Rictor) and MLCST8, is rapamycin insensitive and 
regulates the AKT phosphorylation. PIP2: Phosphatidylinositol (4,5)-bisphosphate; PIP3: 
Phosphatidylinositol (3,4,5)-trisphosphate. The figure was taken from (Ravikumar et al., 2010). 
Besides the PI3K/AKT/mTORC1 pathway, other signaling pathways can also regulate 
autophagy such as AMP-activated protein kinase (AMPK), glycogen synthase kinase 3 
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beta (GSK3) and amino acid. Inositol-1,4,5-trisphosphate (IP3) and its receptor (IP3R) 
control the calcium translocation from endoplasmic reticulum (ER) to mitochondria 
where enough ATPs are generated to activate AMPK. AMPK induces autophagy through 
phosphorylation of TSC2 to suppress mTORC1 expression (Cardenas et al., 2010; Criollo 
et al., 2007; Sarkar and Rubinsztein, 2006). GSK3 can also phosphorylate TSC2 to 
induce autophagy while the essential amino acid suppresses autophagy by activating 
mTORC1. Rapamycin as an inhibitor of mTORC1 can be used to induce autophagy.  
 
Apart from the mTOR pathway, there are some other mTOR-independent proteins that 
are also involved in the autophagy regulation. For instance, second messenger cAMP 
negatively regulates autophagy through the inhibition of ATG1, ATG8 and ATG13 (Graef 
and Nunnari, 2011). The human tumor suppressor P53 possesses a dual role on regulating 
autophagy. Cytoplasmic P53 suppresses autophagy while nuclear P53 induces autophagy 
in response to the cell trauma such as DNA damage (Maiuri et al., 2010; Ryan, 2011). 
Chromatin remodeling enzymes, such as histone acetyltransferases HDAC6 and 
SIRTUIN-1 could negatively modulate autophagy (Simms-Waldrip et al., 2008). 
Collectively, the complex regulation of signaling pathways involved in autophagy allows 
cells to maintain catabolism and metabolism.   
1.3.3 EPG5 functions as an autophagy regulator 
Initially, EPG5 was discovered as a key regulator of the autophagy pathway in C. elegans 
for autolysosome formation to degrade metabolic waste (Tian et al., 2010). Knockdown 
of epg5 with siRNA in C. elegans caused severe accumulation of autophagosomes that 
were demonstrated by the lc3ii positive puncta. Additionally, in the intestinal cells of 
epg5 mutant C. elegans, abnormal hybrid of late endosomes and lysosomes indicated a 
new role of epg5 in lysosome biogenesis. The blockade of fusion of autophagosomes 
with lysosomes was observed in EPG5-mutant fibroblasts from patients with Vici 
syndrome (Cullup et al., 2013). Furthermore, the importance of epg5 was further 
confirmed in the epg5-knockout mice, which demonstrated phenotypes similar to that of 
ALS disease including muscle denervation, myofiber atrophy, late-onset progressive 
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hindquarter paralysis and dramatically reduced survival. The phenotype of 
epg5-knockout mice recapitulates the autophagy defects and skeletal muscle myopathy 
seen in patients with Vici syndrome (Zhao et al., 2013). Recent studies with conditional 
epg5-knockout drosophila revealed a loss of function of retinal photoneurons and the 
autophagy defect (Byrne et al., 2016b). Taken together, EPG5 is essential for maintaining 
basal autophagy to keep the cell in homeostasis.  
1.3.4 Mutations in EPG5 cause Vici syndrome 
In 2013, Thomas Cullup and his colleagues discovered that mutations in EPG5 
(previously KIAA1632) caused Vici syndrome. They performed exome and Sanger 
sequencing analysis in 18 patients with Vici syndrome, which included 11 European, 3 
Arab, 2 Turkish, 1 Japanese and 1 British-Asian origin (Cullup et al., 2013). In 2016, 
additional 20 affected individuals were recruited in the study. They identified a total of 39 
different EPG5 mutations; 55% homozygous and 45% compound heterozygous 
mutations (Byrne et al., 2016b). From the family history, they found 43% parental 
consanguinity, corresponding to the efficiency of the homozygous mutation. The 
mutation of EPG5 in patients proves to be a valuable marker and utility gene card for 
diagnosing Vici syndrome (Cullup et al., 2014).  
1.4 Application of iPSCs in disease modeling and drug screening  
1.4.1 Patient-specific iPSCs used for disease modeling 
To elucidate the molecular mechanism of genetic disorders, hiPSCs are used to model the 
disease in a culture system in vitro. HiPSCs are able to differentiate into different cell 
types such as neurons, hepatocytes, smooth muscle cells, cardiomyocytes and endothelial 
cells, which are difficult to be isolated from the patient tissues (Choi et al., 2009; Hu et al., 
2010; Lian et al., 2012; Liu et al., 2016; Spence et al., 2011; Sullivan et al., 2010; Takebe 
et al., 2013; Zhang et al., 2009). These differentiated cells derived from patient-specific 
iPSCs could recapitulate the disease phenotypes in variety of diseases that included 
monogenic disorders which are caused by single gene defect e.g. Lesch-Nyhan disease 
and fragile X syndrome (Eiges et al., 2007; Urbach et al., 2004), complex disorders 
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resulting from multiple gene defects, such as autism spectrum disorder and schizophrenia 
(Brennand et al., 2011; DeRosa et al., 2012), early-onset disorders diagnosed during 
childhood such as Turner and Down syndrome (Morris et al., 1999), and late-onset 
disorders which occur in adult life such as Parkinson and Alzheimer diseases (Devine et 
al., 2011; Yagi et al., 2011). Modeling cardiac diseases with hiPSC technology also 
represents an attractive and viable approach to study cardiac disease progression, 
signaling pathways as well as drug mechanism of action in human cardiomyocytes 
(Figure 3). Some human cardiac diseases e.g. long-QT syndrome, Barth syndrome and 
catecholaminergic polymorphic ventricular tachycardia have been successfully modeled 
with cardiomyocytes derived from patient-specific iPSCs (Davis et al., 2012; Dudek et al., 
2016; Itzhaki et al., 2011).  
 
Figure 3. iPSCs as a platform for disease modeling and drug screening. Somatic cells from 
patients are harvested and reprogrammed to yield iPSCs. The cells are then differentiated into 
specific cell types that are used to model the disease condition. These differentiated cells are then 
used in compound screening and drug validation. The figure was taken from (Grskovic et al., 
2011). 
 
The iPSCs platform has also been used to recapitulate the disease phenotype and to study 
molecular mechanisms of autophagy and lysosome defective diseases, particularly the 
lysosomal storage disorder. For instance, Gaucher disease (GD) is a genetic disorder 
caused by mutations in the β-glucocerebrosidase gene, which lead to the abnormal 
accumulation of glucocerebroside in spleen, liver, kidneys, lungs, brain and bone marrow. 
Neuronal cells derived from GD-specific iPSCs showed widespread lysosomal depletion, 
autophagosome accumulation and significantly downregulated expression of TFEB 
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(transcription factor EB), a master regulator of lysosome biogenesis (Awad et al., 2015). 
Another example is Pompe disease, caused by the deficiency of lysosomal acid 
alpha-glucosidase, which is an autosomal recessive metabolic disorder. Cardiomyocytes 
derived from Pompe disease-specific iPSCs showed a Golgi-based glycosylation deficit 
but without autophagosome accumulation detected by LC3II (Raval et al., 2015). Taken 
together, these disease-specific iPSCs provide researchers a suitable human disease 
model to understand the disease progression and possibly discover new biomarkers for 
drug discovery. 
1.4.2 Patient-specific iPSCs used for drug screening 
Drug screening strategies using iPSCs have been developed and applied to high 
throughput screening (Avior et al., 2016) (Figure 3). The studies were firstly performed 
based on the diseased mouse neurons, and then the selected drugs were further tested on 
motor neurons and astrocytes derived from ALS patient-specific iPSCs (Barmada et al., 
2014; Dimos et al., 2008; Sances et al., 2016). New candidates of drugs such as Taxol, 
isoxazole, NAB2, GW5074 and co-enzyme Q10 for neuron dysfunctional diseases were 
discovered by using the patient-specific iPSC models since 2009 (Cooper et al., 2012; 
Lee et al., 2009; Ren et al., 2015; Ryan et al., 2013; Shcheglovitov et al., 2013). 
Niemann-Pick disease type C (NPC) is a lysosomal storage disease with abnormal 
accumulation of cholesterol and glycolipids. A potential new drug 
2-hydroxypropyl-γ-cyclodextrin was discovered to target this disease by reducing 
cholesterol accumulation in hepatocyte-like cells and neural progenitors derived from 
NPC-specific iPSCs in vitro (Soga et al., 2015). Cardiomyocytes derived from iPSCs, 
which exhibit the similar characteristics of human embryonic cardiomyocytes, including 
structural, molecular, functional properties and response with specific drugs, provide a 
good platform for screening the anti-arrhythmic drugs and exploring the cardiac toxic 
tests (Liang et al., 2013).  
1.4.3 Genomic editing of iPSCs using the CRISPR/Cas9 technique 
To achieve the specific gene modification, the CRISPR/Cas9 (clustered regularly 
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interspaced short palindromic repeat (CRISPR) and CRISPR associated endonuclease 9 
(Cas9)) system in the prokaryotic was quickly adapted for genomic editing in eukaryotic 
systems including Drosophila, C. elegans, zebrafish, mouse, rat and human (Cho et al., 
2013; Cong et al., 2013; DiCarlo et al., 2013; Gratz et al., 2013; Hwang et al., 2013). 
Genomic DNA editing in mammalian cells were also achieved by using the zinc-finger 
nuclease (ZFN) and transcription-activating protein (TALEN) systems, which are applied 
for inserting or rescuing mutation sites in genes for understanding their functions 
(Bibikova et al., 2003; Bibikova et al., 2002; Boch et al., 2009; Moscou and Bogdanove, 
2009). When compared with the ZFN and TALEN technologies, the CRISPR/Cas9 
technique has higher efficiency to generate nucleotide(s) insertion or deletion via 
non-homologous end joining (NHEJ) and homologous recombination (HR), which 
conveniently allows for new discovery of gene functions and molecular mechanisms of 
human genetic diseases. Using gene-editing techniques such as CRISPR/Cas9 and 
specific guide RNA (sgRNA), single nucleotide gene correction was introduced into 
hiPSCs, which was to model the disease carrying specific gene mutations (Gonzalez et al., 
2014) and to “correct” causative mutation in monogenic recessive disorders such as 
cystic fibrosis, sickle–cell anemia or Duchene muscular dystrophy (Mali et al., 2013b). 
The CRISPR/Cas9 gene correction approach was introduced to rectify an aberrant copy 
of the cystic fibrosis transmembrane conductor receptor (CFTR) gene in intestinal stem 
cells of cystic fibrosis patients, resulting in “gene-corrected” stem cells from these 
patients, which were able to form stable epithelial organoids (Schwank et al., 2013).  
1.4.4 Engineered heart muscle generated from iPSCs-derived cardiomyocytes 
Engineered heart muscles (EHMs) are 3-dimensional cardiac tissues generated from the 
assembly of cardiomyocytes and cardiac supportive non-myocytes in a hydrogel mixture. 
These tissues provide necessary environmental cues to improve the maturation of 
hiPSC-derived cardiomyocytes, including sarcomere structure and arrangement, gene 
expression, contractility and particularly maturation of the ion channels (Eder et al., 
2016). Compared to monolayer cardiomyocyte cultures, EHMs are physiologically more 
relevant, as they possess similar complex structures and functions of the native heart 
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tissue (Mathur et al., 2016). Previous data show that EHMs generated from 
hiPSCs-derived cardiomyocytes could be used to demonstrate the contractile function of 
normal and diseased cardiac tissues in vitro (Mannhardt et al., 2016). 
1.5 Aim of this study 
In this study, we recruited a patient (3-month-old) with Vici syndrome. Previous gene 
analysis revealed that the patient carries a homozygous intronic mutation in EPG5 
(c.4952+1G>A). Based on sequencing of cDNA derived from patient fibroblast cultures, 
this mutation was predicted to result in a frame shift and premature stop codon insertion, 
p.Phe1604Glyfs*20 (Cullup et al. 2013). Conformational analysis of fibroblasts derived 
from this patient also showed autophagosome accumulation due to the impaired 
autophagosome-lysosome fusion (Cullup et al., 2013). However, it was not elucidated 
whether the cardiomyocytes (CMs) showed the same phenotype in comparison to 
fibroblasts and if the impaired autophagy was the direct consequence of the EPG5 
mutation.  
 
The aims of this thesis are to study Vici syndrome associated cardiomyopathy using 
patient-specific iPSCs as a disease model in vitro and to elucidate the molecular 
mechanisms of the autophagy pathway in CMs. The main objectives are: 
 
 Generation of iPSCs from the patient with Vici syndrome carrying the EPG5 mutation 
(c.4952+1G>A). 
 “Proof of pluripotency” of the generated patient-specific iPSCs. 
 Analysis of the disease phenotype and the autophagy pathway in CMs derived from 
Vici-iPSCs (Vici-iPSC-CMs). 
 Correction of the mutation in EPG5 in Vici-iPSCs by using the CRISPR/Cas9 
technology. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Oligonucleotides 
Name Sequence (5'-3') Annealing Temp (°C) Cycle Size (bp) 
EPG5_1  for: AACCGCAGCTCTTCGGGA AT 
rev: CTAATGCCAACTTTCTGAATCCCA 






56 37 330 
EPG5_3 
 
for: CCT TGGCATGGAGTTGGT TTG 
rev: CTCACAATTCAGGGGTCAGC 
58 36 1076 
FOXD3 for: GTGAAGCCGCCTTACTCGTAC 
rev: CCGAAGCTCTGCATCATGAG 
58 38 353 
GAPDH for: AGAGGCAGGGATGATGTTCT 
rev: TCTGCTGATGCCCCCATGTT 
58 30 258 
GDF3 for: TTCGCTTTCTCCCAGACCAAGGTTTC 
rev: TACATCCAGCAGGTTGAAGTGAAC 
AGCACC 
58 32 311 
LIN28 for: AGTAAGCTGCACATGGAAGG  
rev: ATTGTGGCTCAATTCTGTGC 
58 36 410 
MYH7 for: GAAGGTGAGTGTCCCAGAGG 
rev: CTTGTAGTCGATGTTCCCCG 
58 32 289 
MYL2 for: GGCGAGTGAACGTGAAAAAT 
rev: CAGCATTTCCCGAACGTAAT 
56 30 200 
NKX2.5 for: GGCCTCAATCCCTACGGTTA 
rev: CACGAGAGTCAGGGAGCTGT 
60 30 308 
SOX2 for: ATGCACCGCTACGACGTGA 
rev: CTTTTGCACCCCTCCCATTT 
58 30 437 
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TNNT2 for: GACAGAGCGGAA AAGTGGGA 
rev: TGA AGGAGGCCAGGCTCTAT 
58 30 305 
EPG5_1: primers for detecting the expression of EPG5 on mRNA level; EPG5_2: primers for detecting 
the mutation site of EPG5 in genomic DNA; EPG5_3: primers for cleavage assay to test the efficiency of 
CRISPR/Cas9/gRNA; GAPDH: Glycerinaldehyde-3-phosphate-dehydrogenase; FOXD3: Forkhead box 
D3; GDF3: Growth differentiation factor-3; MYH7: Myosin heavy chain 7; MYL2: Myosin light chain 2; 
NKX2.5: NK2 homeobox 5; TNNT2: Troponin T type 2.  
 
Single-stranded oligonucleotides of EPG5 were used for correction of the EPG5 mutation in the 
CRISPR/Cas9 experiments, as following:  
AGTGAAGCAGTTGCAAGCAGAAGCTGCTAAACCACCAAGCTTAAATATTGTAGAAGCTGCTGT
ACATGCAGAAAACTTGATCACGTAAGTTTTGCAGGCATTATAATTTGAAATACTGTTTTG 
2.1.2 Primary antibodies 
Antigen Type Supplier Catalog No. Dilution 
AFP Polyclonal rabbit IgG Dako A0008 IF: 1:200 
AKT Monoclonal rabbit IgG CST 4691 WB: 1:1000 
AKT S473 Monoclonal rabbit IgG CST 9271 WB: 1:1000 
AKT T308 Monoclonal rabbit IgG CST 2965 WB: 1:1000 
COXIV Monoclonal rabbit IgG CST 4850 IF: 1:100 
cTNT Monoclonal mouse IgG Thermo 
Fisher 
Scientific 
MS295PABX IF: 1:200 
CX43 Polyclonal rabbit IgG Abcam Ab11370 IF: 1:200 
FOXO3 Monoclonal rabbit IgG CST 2467 WB:1:1000 
FOXO3 T32 
FOXO1 T24 
Monoclonal rabbit IgG CST 9464 WB: 1:1000 
GAPDH Polyclonal rabbit IgG Abcam ab9485 WB: 1:1000 
LAMP1 Monoclonal mouse IgG Abcam ab25630 IF: 1:100 
LC3 Monoclonal rabbit IgG CST 3868 IF: 1:100, WB:1:1000 
LIN28 Polyclonal goat IgG R&D AF3757 IF: 1:300 
MLC2V Monoclonal rabbit IgG Protein tech 10906-1-AP IF: 1:200 
mTOR Monoclonal rabbit IgG CST 2983 WB: 1:1000 
mTOR S2448 Monoclonal rabbit IgG CST 2971 WB: 1:1000 
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NANOG Polyclonal rabbit IgG Thermo 
Fisher 
Scientific 
PA1-097 IF: 1:100 
NBR1 Monoclonal mouse IgG Abcam ab55474 IF: 1:100, WB:1:1000 
OCT4 Polyclonal goat IgG R&D AF1759 IF: 1:40 
P62 Monoclonal rabbit IgG Abcam ab109012 IF:1:100, WB:1:1000 
P70S6K Monoclonal rabbit IgG CST 2708 WB: 1:1000 
P70S6K T389 Monoclonal rabbit IgG CST 9234 WB: 1:1000 
Phalloidin- 
iFluor 647 
Fluorescent iFluor647 dye 
for F-ACTIN 
Abcam  ab176759 IF: 1:100 
 
SMA Monoclonal mouse IgG Sigma A2547 IF: 1:1000 
SSEA4 Monoclonal mouse IgG Thermo 
Fisher 
Scientific 
MA1-021 IF: 1:100 
α-ACTININ Monoclonal mouse IgG Sigma A7811 IF: 1:1000 
β-III-TUBULIN Monoclonal mouse IgG Covance MMS-435P IF: 1:1000 
AFP: Alpha-1-fetoprotein; AKT S473: AKT serine 473; AKT T308: AKT threonine 308; COXIV: 
Cytochrome c oxidase subunit IV; cTNT: Cardiac troponin T; CX43: Connexin 43; FoxO3: Forkhead box 
O3; FoxO3 T32: FOXO3 threonine 32; FOXO1: Forkhead box O1; FOXO1 T24: FOXO1 threonine 24; 
LAMP1: Lysosomal associated protein 1; MLC2V: Myosin light chain 2V; P70S6K: Ribosomal protein 
S6 kinase, 70 kDa, polypeptide 1; P70S6K T389: P70S6K threonine 389; Phalloidin-iFluor 647: Far-red 
fluorescent dye for F-ACTIN; SMA: Smooth muscle actin; SSEA4: Stage-specific embryonic antigen-4.  
2.1.3 Secondary antibodies 
Name Supplier Catalog No. Dilution 
Cy3-conjugated donkey-α-goat IgG Jackson ImmunoResearch 705-166-147  IF: 1:600 
Cy3-conjugated goat-α-mouse IgG Jackson ImmunoResearch 115-165-068 IF: 1:600 
Cy3-conjugated goat-α-rabbit IgG Jackson ImmunoResearch 111-165-003 IF: 1:300 
FITC-conjugated goat-α-mouse IgG Jackson ImmunoResearch 115-096-072 IF: 1:300 
FITC-conjugated goat-α-rabbit IgG Jackson ImmunoResearch 111-095-045 IF: 1:300 
HRP-conjugated anti-mouse IgG Sigma RABHRP2 WB: 1:3000 
HRP-conjugated anti-rabbit IgG Sigma RABHRP1 WB: 1:3000 
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2.1.4 Commercial kits 
Name Supplier Catalog No. 
Alkaline phosphatase staining kit Sigma 86R-1KT 
Genomic cleavage detection kit Thermo Fisher Scientific A24372 
Human stem cell nucleofector kit 2 Lonza VPH-5022 
TransIT-293 reagent Mirus 41094613 
QIAprep Spin Maxiprep kit Qiagen 12163 
QIAprep Spin Miniprep kit Qiagen 27104 
QIAquick gel extraction kit Qiagen 28704 
Maxwell 16 cell DNA purification kit  Promega AS1020 
SV total RNA isolation kit Promega Z3105 
2.1.5 Cell lines 
Name Cell type 
isWT1BLD2 Human iPSCs from a healthy donor generated in Dr. Guan’s lab 
MEFs Mouse embryonic fibroblasts isolated from 15-17-day-old embryos of NMRI mice 
Vici FB Human fibroblasts from the Vici patient obtained from Dr. Gautel’s lab 
iBM76.3 Human iPSCs from a healthy donor generated in Dr. Guan’s lab 
WTD2-1 Human iPSCs from a healthy donor generated in Dr. Guan’s lab 
iVici1.2 Human iPSCs from the Vici patient generated in this study 
iVici1.3 Human iPSCs from the Vici patient generated in this study 
iVici1.5 Human iPSCs from the Vici patient generated in this study 
2.1.6 Basal media, growth factors, cytokines and drugs for cell culture 
Name Supplier Catalog No. 
0.05% Trypsin-EDTA Life technologies 25300054 
0.25% Trypsin-EDTA Life technologies 25200056 
2.5% Trypsin Life technologies 15090046 
TrypLE Express Life technologies 1734778 
Materials and Methods 
 27 
4′,6-Diamidino-2-phenylindole (DAPI) Sigma D9542 
60% Sodium DL-lactate solution  Sigma L4263 
7.5% Bovine albumin fraction V (BSA) Life technologies 15260037 
Albumin, human recombinant Sigma A0237 
Bafilomycin A1 Sigma B1793 
Basic fibroblast growth factor (bFGF) PeproTech 100-18B 
Bovine serum albumin (BSA) Sigma F7524 
B27 supplement Life technologies 17504044 
CHIR99021 Merck Millipore 361559 
Collagenase type II Worthington LS004176 
Collagenase type IV Worthington LS004189 
Dimethyl sulfoxide (DMSO) Sigma D2650 
Dulbecco´s modified Eagle medium (DMEM) Life technologies 11960044 
DMEM/F-12 with GlutaMax Life technologies 31331028 
Dulbecco´s phosphate buffered saline (DPBS) Life technologies 14190094 
Essential 8 (E-8) basal medium  Life technologies A1517001 
Ethylenediaminetetraacetic acid (EDTA) Sigma E6758 
Fetal bovine serum (FBS) Sigma F7524 
Gelatin Sigma 48720 
Geltrex Life technologies A1413301 
HEPES Buffer (1 M, pH 7.0-7.6) Sigma H0887 
Inhibitor of WNT production-2 (IWP2) Merck Millipore 68167 
Iscove´s modified Dulbecco´s medium (IMDM) 
with GlutaMax 
Life technologies 31980022 
IMDM with HEPES without GlutaMax HyClone SH30259.01 
Isopropanol Merck Millipore 1096341000 
Isoproterenol Sigma I2760 
Knockout serum replacement (KSR) Life technologies 10828028 
L-ascorbic acid 2-phosphate  Sigma A8960 
L-glutamine, 100x Life technologies 25030081 
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Lipofectamine 2000 life technologies 11668019 
Medium 199 Sigma M 4530 
Mitomycin C Serva Electrophoresis 29805.02 
Monothioglycerol (MTG) Sigma M6145 
Non-essential amino acids (NEAA), 100x Life technologies 11140035 
Opti-MEM® I reduced serum medium Life technologies 31985070 
Penicillin-streptomycin solution, 100x Life technologies 15140122 
Phenylephrine Sigma P6126 
Polybrene (hexadimethrine bromide) Sigma 107689  
Pro survival factor (PSF) Merck Millipore 529659 
Rapamycin Sigma R0395 
Rat collagen  Produced by the Wolfram-Hubertus 
Zimmermann’s group 
Roswell Park Memorial Institute (RPMI) 1640 medium with 
GlutaMax 
Life technologies 72400021 
RPMI 1640 (w/o glucose) Life technologies 11879020 
StemPro accutase cell dissociation reagent Life technologies A1110501 
STEMCCA vector provided by Prof. Kotton, Boston 
University School of Medicine 
Thiazovivin (TZV) Merck Millipore 420220 
Trypsin powder Life technologies 27250018 
Versene solution Life technologies 15040066 
β-mercaptoethanol Serva Electrophoresis 28625 
STEMCCA vector: The Cre-excisable STEMCCA vector contains four transcription factors OCT4, KLF4, 
SOX2, and c-MYC, which separated by the self-cleaving 2A peptide and internal ribosome entry site 
sequences. This vector also contains two loxP sites for removing the transgenic genes with Cre-mediated 
excisable system following reprogramming (Somers et al., 2010). 
2.1.7 Stock solutions for cell culture 
Drugs Components  
bFGF 50 g/ml 1 mg bFGF 
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20 ml 5 mM Tris  
Store aliquots at -20°C 
bFGF 5 g/ml 
 
200 μl (50 g/ml stock) 
1800 μl 0.1% BSA/DPBS 
Store at 4°C not longer than two weeks 
β-mercaptoethanol (100x) 35 μl β-mercaptoethanol 
50 ml DPBS 
Filtrate with 0.22 μm Steriflip filter 
1% BSA/DPBS 1 ml 7.5% BSA 
6.5 ml DPBS 
0.1% BSA/DPBS 0.1 ml 7.5% BSA 
7.4 ml DPBS 
0.1% Trypsin-EDTA 0.1 g trypsin 
0.1 g EDTA 
100 ml H2O 
1% Gelatin 1 g gelatin 
100 ml H2O 
Autoclave, and store at 4°C 
Collagenase II (46 U/ml) 1 mg collagenase II (46 U/mg) 
1 ml RPMI 
Store aliquots at -20°C 
Collagenase IV (200 U/ml) 1 mg collagenase IV (200 U/mg) 
1 ml DMEM/F-12 
Store aliquots at -20°C 
CHIR99021 (12 mM) 5 mg CHIR99021 
894 μl DMSO 
Store aliquots at -20°C 
IWP2 (5 mM) 10 mg IWP2 
4.28 ml DMSO  
37 °C 10 min 
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Store aliquots at -20°C 
Lactate/HEPES (1 M) 3 ml 60% w/w sodium DL-lactate 
18 ml 1 M HEPES 
Store aliquots at -20°C 
Mitomycin C (200 μg/ml) 200 μg mitomycin C 
1 ml DPBS 
Store aliquots at -20°C 
MTG (150 mM) 13 µl MTG  
1 ml IMDM 
Filtrate with 0.22 μm Steriflip filter 
Freshly prepared before use 
Polybrene (1 mg/ml) 1 mg polybrene 
1 ml H2O 
Filtrate with 0.22 μm Steriflip filter 
Store aliquots at -20°C 
PSF (5 mM) 10 mg PSF 
6.8 ml DMSO 
Store aliquots at -20°C 
Rapamycin (50 μM) 1 mg rapamycin  
1.093 ml DMSO 
Store aliquots at -20°C 
Bafilomycin (100 μM) 5 mg bafilomycin A1  
161 μl DMSO 
Store aliquots at -20°C 
Isoproterenol (250 μM) 6.1925 mg isoproterenol  
1 ml DMSO 
Store aliquots at -20°C 
Phenylephrine (50 mM) 10.1835 mg phenylephrine  
1 ml H2O 
Store aliquots at -20°C 
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2.1.8 Cell culture media  
Medium Name Components 
Cardiac culture medium RPMI 1640 medium with GlutaMax 
1x B27 supplement 
Cardiac differ medium  RPMI 1640 medium with GlutaMax 
0.05% albumin  
0.02% ascorbic acid 
Cardiac selection medium RPMI 1640 without glucose 
2 ml 1 M lactate 
E-8 freezing medium E-8 medium  
20% DMSO 
PSF (5 μM) 
E-8 medium E-8 basal medium 
E-8 essential supplement 
Freezing medium DMEM 
20% FBS 
2% DMSO 
hEHM medium IMDM with HEPES without GlutaMax 
20% FBS 
1x L-glutamine  
1x NEAA  
1x β-mercaptoethanol  
hES medium  DMEM/F-12 with GlutaMax 
15% KSR 
1x NEAA 
bFGF (10-20 ng/ml) 
HFBM DMEM 
10% FBS 
1x β-mercaptoethanol  








bFGF (10-20 ng/ml) 
Iscove Medium  IMDM with GlutaMax 
20% FBS 
1x NEAA 
MTG (150 mM) 
MEF medium  DMEM 
10% FBS 
1x glutamine 
2.1.9 Chemicals and reagents for molecular biological analysis 
Name Supplier Catalog No. 
Acetone J.T.Baker 408 
Agarose Peqlab 35-1020 
Ammonium persulfate (APS) Sigma A3678 
Boric acid Sigma 15663 
Bromphenol blue Sigma 1062 
Calcium chloride (CaCl2) Sigma C1016 
Color prestained protein standard, broad range (11–245 
kDa) 
NEB P7712 
Diethylpyrocarbonate (DEPC) water Ambion AM9915G 
DNA agar Peqlab A3477.0500 
dNTP mix Bioline Bio39029 
Ethanol J.T.Baker L216-07 
Ethidium bromide Carl Roth 2218 
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Fluoromount-G eBioscience 00-4938-02 
GeneRulerTM 100 bp Plus DNA ladder Thermo Fisher 
Scientific 
0321 
Glacial acetic acid Merck Millipore 1.00063.1000 
Glucose Sigma G8270 
Glycine Carl Roth T873 
GoTaq DNA polymerase Promega M3175 
Hind III restriction enzyme NEB R0104S 
Hydrochloric acid (HCl) J.T.Baker 2612 
Immobilon Western chemiluminescent HRP substrate Merck Millipore WBKLS0500 
LB agar Applichem 416106.1210 
Lysogeny broth (LB) powder Applichem A0954 
Magnesium chloride (MgCl2) Sigma M8266 
Methanol J.T.Baker  8402 
MuLV reverse transcriptase (50 U/μl) Life technologies N808-0018 
Nonfat dry milk Sigma M7409 
NP 40 Thermo Fisher 
Scientific 
85125 
Oligo d(T)16 (50 μM) Life technologies N808-0128 
Paraformaldehyde (PFA) Sigma 158127 
Polyvinylidene fluoride (PVDF) membrane  Millipore IPVH00010 
Ponceau S solution Sigma P7170 
Potassium chloride (KCl) Sigma P9333 
Quick coomassie blue staining solution Generon GEN-QC-STAIN-1L 
RNase inhibitor (20 U/μl) Life technologies N808-0119 
Sodium bicarbonate (NaHCO3) Sigma S5761 
Sodium chloride (NaCl) Carl Roth P3957 
Sodium dodecyl sulfate (SDS) Carl Roth 2326 
Sodium hydroxide (NaOH) J.T.Baker 3722 
Sodium phosphate monobasic (NaH2PO4) Sigma S8282 
Tetramethylethylenediamine (TEMED) Carl Roth 2367 
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Tris Carl Roth 5429 
Triton X100 Sigma X100 
Tween 20 Bio Rad 170-6531 
Urea Carl Roth 3941 
Western blot gel Thermo Fisher 
Scientific 
NW04120BOX 
2.1.10 Buffers and solutions for molecular biological analysis 
Names Components 
1.5% Agar gel 1.5 g DNA agar 
100 ml TB buffer  
10% APS  10 g APS 
100 ml H2O 
4% PFA 4 g PFA 
100 ml DPBS 
Blue loading buffer (100 ml, 5x) 31.25 ml 1 M Tris-HCl (pH 6.8) 
10 g SDS  
5 mg bromphenol blue 
57 ml glycerin (87%) 
11 ml β-mercaptoethanol 
CaCl2 (2.25 M) 165.57 g CaCl2 
500 ml H2O 
Cell lysis buffer (RIPA buffer) 150 mM NaCl 
1.0% NP-40  
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris 
0.6 mM DAPI 0.21 mg DAPI 
1 ml H2O 
Fixation buffer 7 ml methanol (ice-cold) 
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3 ml glacial acetic acid (ice-cold) 
LB agar medium 10 g tryptone 
5 g yeast extract 
10 g NaCl 
15 g LB agar 
950 ml H2O 
LB medium 10 g tryptone 
5 g yeast extract 
10 g NaCl 
950 ml H2O 
MgCl2 (1.05 M) 106.83 g MgCl2 
500 ml H2O 
Running buffer (5x) 30.2 g Tris 
144 g glycine 
10 g SDS 
2 l H2O 
Stem I buffer 175 g NaCl 
10 g KCl 
20 ml CaCl2 (2.25 M) 
25 ml MgCl2 (1.05 M) 
955 ml H2O 
Stem II buffer 50 g NaHCO3  
1000 ml H2O 
Stem III buffer 5.8 g NaH2PO4 
1000 ml H2O 
Transfer buffer (10x) 39.4 g Tris 
144 g glycine 
2000 ml H2O 
Tris-borate buffer (TB buffer, 5x) 108 g Tris 
55 g boric acid 
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2000 ml H2O 
Tris-buffered saline with Tween 20 (TBST, 1x) 48.4 g Tris 
58.48 NaCl 
10 ml Tween 20  
1990 ml H2O 
1 M Tris-HCl (pH 6.8) 121.14 g Tris 
HCl to pH 6.8 
Adding H2O to1000 ml 
Tris-SDS (4x, pH 6.8) 6.05 g Tris 
0.4 g SDS 
HCl to pH 6.8 
Adding H2O to100 ml  
Tris-SDS (4x, pH 8.8) 45.5 g Tris 
1 g SDS 
NaOH to pH 8.8 
Adding H2O to 250 ml 
Tyrode buffer  40 ml Stem I buffer 
38 ml Stem II buffer  
10 ml Stem III buffer 
1 g glucose 
100 mg L-ascorbic acid 
pH value regulation: dissolve the chemicals in H2O and adjust the pH value with appropriate volume of 
concentrated HCl or NaOH, thereafter, bring to final volume with H2O. 
2.1.11 Lab equipment and other materials 
Equipment and other materials Manufacturer Catalog No. 
0.22 μm Steriflip filter Merck Millipore SLGSM33SS 
1.5 ml brown tube Eppendorf 0030120.191 
1.5 ml tube Eppendorf AM12400 
10 ml pipette Sarstedt 86.1254.001 
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15 ml falcon Sarstedt 62.554.002 
2 ml glass pipette  Hirschmann 1000141 
25 ml pipette Sarstedt 86.1685.001 
5 ml glass pipette Hirschmann 1101153 
5 ml pipette Sarstedt 86.1253.001 
50 ml falcon Sarstedt 62.547.004 
50ml filter falcon Merck Millipore SCGP00525 
Benchtop Tissue Processor 1020 Leica Biosystems 1491020US01 
Cell culture (untreated) 6-cm dish Sarstedt 82.1194.500 
Cell culture 10-cm dish CytoOne Starlab CC7682-3394 
Cell culture 12-well plate  CytoOne Starlab CC7682-7512 
Cell culture 24-well plate CytoOne Starlab CC7682-7524 
Cell culture 3-cm dish CytoOne Starlab CC7682-3340 
Cell culture 48-well plate Thermo Fischer 
Scientific 
150687 
Cell culture 6-cm dish CytoOne Starlab CC7682-3359 
Cell culture 6-well plate CytoOne Starlab CC7682-7506 
Cell culture 96-well plate Thermo Fischer 
Scientific 
167008 
Cell culture bench HERA 51013961 
Cell culture incubator HERA 5103568 
Cell Scraper Sarstedt 83.1830 
Centrifuge Thermo Fischer 
Scientific 
5415 
ChemiDoc™ MP system Bio-Rad 1708280 
Casy cell counter  Roche  
DNA gel running cassette BioRad 1704402 
FACSCanto II BD  
FACS Aria II BD  
Filter 50 µm BD 340629 
Filtertips 0.1-10 µl CytoOne Starlab S1120-3810  
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Filtertips 100-1000 µl CytoOne Starlab S1122-1830  
Filtertips 1-100 µl CytoOne Starlab S1120-1840  
Glass bottle 100 ml Th.Geier 9.072 011 
Glass bottle 1000 ml Th.Geier 9.072 016 
Glass bottle 250 ml Th.Geier 9.072 012 
Glass bottle 50 ml Th.Geier 9.072 020 
Glass bottle 500 ml Th.Geier 9.072 .015 
Laser scanning microscope  Zeiss LSM510 
Nanodrop spectrophotometer Thermo Fischer 
Scientific 
ND-2000 
PCR machine Sensoquest 012-103 
pH meter level 1 Inolab ba12217e 
Pipette boy Accu-jet pro 5281090 
Water bath machine Thermo Fischer 
Scientific 
18005A-1CEQ 
WB running cassette BioRad 1658004 
2.1.12 Software 
Name Name 
Adobe Illustrator 2015 Alpha image 
AMON/BMON Adobe Photoshop 2015 
Carl Zeiss AxioVision Rel 4.8 Chromas 
Flowing software GraphPad Prism 6 
Image Lab 5     Image J       
Zen 2009  
2.2 Methods 
2.2.1 Cell culture 
All cell cultures were incubated at 37°C and 5% CO2 under humidified conditions in 
incubators.  
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2.2.1.1 Cultivation of human fibroblasts  
Fibroblasts from the patient with Vici syndrome were obtained from Dr. Mathias Gautel’s 
lab (Kings College, London) and cultured in HFBM supplemented with 10 ng/ml bFGF. 
For passaging, fibroblasts were rinsed with 0.1% trypsin-EDTA once following aspiration 
of the culture medium. The cells were then incubated with 0.1% trypsin-EDTA for 3 min 
at 37°C to allow cell detachment. Equal volume of HFBM was subsequently added to 
neutralize the action of trypsin. The total cell suspension was collected and allowed to 
pellet in a centrifuge at 200 x g for 5 min at room temperature. After aspirating the 
supernatant, the cells were plated into new cell culture dishes at a ratio of 1:3-1:6 
depending on the culture density.  
2.2.1.2 Generation of iPSCs from fibroblasts derived from the patient with Vici 
syndrome  
To generate Vici-iPSCs, patient-derived fibroblasts were reprogrammed by transduction 
of the cells with the STEMCCA lentivirus system containing OCT4, SOX2, KLF4 and 
c-MYC in a single plasmid, as described previously (Streckfuss-Bomeke et al., 2013). 
Briefly, 24 h prior to the transduction, fibroblasts were passaged into a 12-well plate at a 
seeding density of 6x10
4
 cells per well. The fibroblasts were transduced with lentivirus 
particles in HFBM at MOI (multiplicity of infection) of 1.0, 2.0 and 3.0 supplemented 
with 1 μg/ml polybrene for 24 h. Polybrene, a cationic polymer, was used to increase the 
efficiency of DNA virus infection into eukaryotic cells (Davis et al., 2002). The virus 
containing medium was then removed 24 h post transduction and fresh HFBM 
supplemented with 10 ng/ml bFGF was added. Subsequent medium was changed daily 
until day 7 post transduction, and the transduced cells were passaged onto 6-cm dishes 
that were coated with 0.2 mg/ml Geltrex at 37°C for 30 min or at 4°C overnight, at a ratio 
of 1:4, 1:5 and 1:6 in HFBM with 10 ng/ml bFGF. 24 h later, medium was changed to E-8 
medium that was used daily until colonies with typical morphology of human pluripotent 
stem cells appeared in the culture dish. The single hiPSC colonies were manually cut with 
sterilized glass pipettes into small pieces and plated onto Geltrex-coated 12-well plates 
under the cell culture bench. These colonies were cultured in E-8 medium and used in 
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this study. 
2.2.1.3 Feeder-free cultivation of hiPSCs  
For feeder-free cultivation of hiPSCs, cell culture dishes were coated with Geltrex for 30 
min at 37°C or overnight at 4°C before use. Both Ctr-iPSCs (hiPSCs derived from 
healthy donors) and Vici-iPSCs were subsequently cultured on these Geltrex-coated 
dishes in E-8 medium. Upon reaching 80-90% confluence, hiPSCs were passaged onto 
new dishes. Briefly, hiPSCs were washed once with Versene and incubated with fresh 
Versene for 4-5 min at room temperature. After aspirating the Versene solution, the 
dissociated cells were re-suspended in E-8 medium with 5  PSF and seeded into the 
new dishes. The medium was then changed daily with E-8 medium.  
2.2.1.4 Isolation of mouse embryonic fibroblasts  
MEFs were isolated from the 15-17-day-old mouse embryos. After the pregnant mouse 
was rinsed in 70% ethanol, the abdomen was opened and the embryos were washed with 
DPBS twice. Then the head and red organs (such as heart, liver and intestinal) were 
removed. The remained tissues were rinsed in 0.2% trypsin and minced into pieces with a 
sterile razor blade. The tissues were then transferred into a 50 ml Erlenmeyer flask 
containing a stir bar with fresh 0.2% trypsin and stirred on magnetic stirrer for 30 min. 
The digested tissues were pipetted up and down several times to aid further dissociation 
of tissue clumps. The suspension was filtered through a sieve or a careen, neutralized 
with equal volume of MEF medium and finally spun at 300 x g in a centrifuge. After the 
supernatant was aspirated, the cells were re-suspended in warm MEF medium and plated 
in tissue culture dishes. The cells were cultured in MEF medium until 80-90% confluent 
and frozen down for future usage. These tubes were then denoted as passage 0 (P0).   
2.2.1.5 Cultivation and inactivation of mouse embryonic fibroblasts 
MEFs were cultured on cell culture dishes in MEF medium for only 4 passages to support 
the growth of hiPSCs. To ensure that the MEFs remain growth arrested during the 
proliferation of hiPSCs, MEFs were incubated with 10 μg/ml mitomycin C for 3-4 h at 
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37°C before use. Thereafter, the cells were rinsed with DPBS 3 times, digested with 0.1% 
trypsin-EDTA, and neutralized with MEF medium. MEFs with an appropriate cell density 




) and cultured in MEF 
medium until use.  
2.2.1.6 Cultivation of hiPSCs on feeder layer 
To cultivate hiPSCs on feeder layer, hiPSCs were rinsed with basal DMEM/F12 twice 
and digested with collagenase IV (200 U/ml) for 3 min at room temperature. The cells 
were then cut into small clusters using the cell scraper, gently pipetted twice and plated 
on the dishes with inactivated MEFs in hES medium. Thereafter, repeated passage of the 
cells was performed every 6-7 days. Differentiated cell regions characterized by the 
presence of cystic areas were mechanically removed during medium change daily.  
2.2.1.7 Spontaneous differentiation of hiPSCs in vitro 
HiPSCs cultured on feeder layer were used for the spontaneous differentiation in vitro to 
prove their pluripotency. Briefly, hiPSCs were washed twice with basal DMEM/F12 and 
digested with collagenase IV (200 U/ml) for 4 min. The cell colonies were cut into bigger 
pieces, re-suspended in hES medium and transferred to low attachment cell culture dishes. 
During the first day, cell clusters round up into compact cell aggregates termed 
“embryoid bodies” (EBs). The next day, EBs were collected and spun at 250 x g for 2 
min in a centrifuge. Supernatant was carefully aspirated and the EBs were cultured in 
Iscove medium until day 8. On day 8, EBs were plated onto 0.1% gelatin-coated cell 
culture dishes for further differentiation. At day 33, differentiated cells were briefly 
rinsed with DPBS and fixed with 4% PFA for 20 min at room temperature for 
immunofluorescence staining.  
2.2.1.8 Direct differentiation of hiPSCs into cardiomyocytes 
Feeder-free culture of hiPSCs in E-8 medium were used for the direct differentiation into 
CMs. Briefly, hiPSCs were first passaged into Geltrex-coated 12-well plates and allowed 
to proliferate for 2-3 days till 80% cell confluence in each well to provide sufficient cells 
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for cardiac differentiation. Cardiac differentiation was initiated by replacing E-8 medium 
with cardiac differ medium supplemented with 4-6 μM CHIR99021 (day 0), an inhibitor 
of GSK3β to induce hiPSCs differentiating into mesendoderm progenitors. After 24 h (on 
day 1), CHIR99021 was removed and cells were maintained in cardiac differ medium. On 
day 3, the cardiac differ medium was supplemented with 2.5 μM IWP2, the Wnt 
antagonist to induce the commitment of mesendoderm progenitors to a cardiac fate. On 
day 5, the medium was replaced with cardiac differ medium. From day 8, the medium 
was changed to cardiac culture medium and the first beating cardiomyocytes were 
observed on day 10-14. To obtain purified cardiomyocytes, the beating cardiomyocyte 
cultures at day 16-20 were enzymatically dissociated into single cells. Briefly, the 
cardiomyocytes were first incubated with collagenase II (46 U/ml) at 37°C for 2 h to 
allow the detachment of cardiomyocytes. Detached cells were collected into 15-ml falcon 
and spun down at 250 x g for 5 min in a centrifuge. In order to obtain the single 
cardiomyocytes, the cells were then treated with 0.25% trypsin for 8 min at 37°C. The 
action of trypsin was neutralized by adding FBS and the total cell suspension was 
pelleted in a centrifuge. The resultant cell pellet was suspended in cardiac culture 
medium and seeded onto new Geltrex-coated dishes. After 4-day cultivation in cardiac 
culture medium, fresh medium was changed to cardiac selection medium (with 
supplementation of lactate instead of glucose) for 4–6 days to metabolically select 
cardiomyocytes, thereby increasing the purity of the CM culture. Afterwards, these 
purified cardiomyocytes were maintained in cardiac culture medium for another 2-3 
months for further experimental studies.  
2.2.1.9 Cryopreserved and thawing of the cultivated cells 
To cryopreserve fibroblasts and hiPSCs, the cells were digested into single cells as 
previously described, accordingly. Afterwards cell pellets were re-suspended in freezing 
medium or E-8 freezing medium according to the culture and then transferred into the 
cryovials. The cryovials containing the cells were kept overnight at -80°C in a freezing 
container with isopropanol and then transferred into liquid nitrogen vapor for extended 
storage.   
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To thaw the cells, frozen cells were retrieved and placed in a 37°C warm water bath. 
After thawing, the cells were immediately immersed into cold fresh medium and spun at 
250 x g for 5 min in a centrifuge. The cells were re-suspended and plated onto new cell 
culture dishes in cell culture medium, respectively. 
2.2.1.10 Nucleofection of hiPSCs 
The custom CRISPR/Cas9-GFP plasmid (Figure 4) with EPG5-specific guide RNA 
(sgRNA) was designed together with Sigma. The plasmid DNA was amplified in E. coli 
bacterial cultures in LB medium with 50 g/ml kanamycin for 36 h. DNA was isolated 
using the QIAprep Spin Maxiprep kit according to the manufacturer’s instructions. After 
analysis of the cleavage efficacy of the designed sgRNA in HEK293T cells (see 2.2.10), 
the CRISPR/Cas9-GFP plasmid DNA together with single-stranded oligonucleotides of 
EPG5 (2.1.1) was introduced into Vici-iPSCs.  
 
For transfection, hiPSCs were digested with 0.05% Trypsin-EDTA for 3 min at 37°C until 
the cells detached. Pre-warmed DMEM with FBS was added to neutralize the 
dissociation action of trypsin-EDTA. Cell numbers were counted with cell counting 
chamber. 3x10
6
 cells were spun down at 200 x g for 5 min. After the supernatant was 
removed, the cell pellet was re-suspended in a mixture of nucleofection buffer A (82 μl) 
and B (18 μl) containing 1.5 μg CRISPR/Cas9-GFP plasmid DNA and 30 ng single- 
stranded oligonucleotides of EPG5. The sample was then transferred to 0.4 m cuvette 
and electrified using the appropriate Nucleofector program B-016 that was initially 
determined for hESCs using the human stem cell nucleofector kit 2. The transfected cells 
were transferred to E-8 medium containing 5  PSF for recovery for 10 min at 37°C. 
Finally, the cells were seeded on the Geltrex-coated 6-well plate with E-8 medium 
containing 5  PSF.   
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Figure 4. The scheme of CRISPR/Cas9-GFP vector. Guide RNA (gRNA) and Cas9 protein are 
expressed in a single vector, which is controlled by the promoter U6 and CMV, respectively. The 
GFP fused with 2A peptide to Cas9 enables to track the efficiency of transfection and to enrich 
the transfected cells through FACS sorting. Figure was taken from Sigma homepage.  
2.2.1.11 Transfection of hiPSC-derived cardiomyocytes 
The hiPSC-derived cardiomyocytes (hiPSC-CMs) were dissociated into single cells and 
cultured as monolayers as described above. Cardiomyocytes were transfected with 
lipofectamine 2000 according to the manufacturer’s recommendations. The 
LC3-GFP-RFP plasmid DNA (Figure 5) was obtained from Prof. Dr. Lucie Carrier 
(Department of Experimental Pharmacology and Toxicology, University Medical Center 
Hamburg-Eppendorf). The plasmid DNA and lipofectamine 2000 reagent were 
individually mixed with Opti-MEM and allowed to incubate at room temperature for 10 
min. Then the DNA mixture was transferred into the lipofectamine 2000 mixture and 
incubated for 5 min. Thereafter, the DNA-lipid complex was gently layered dropwise 
onto the cultured cardiomyocytes. The cells were fixed by 4% PFA for confocal images 
48 h after transfection.  
 
Figure 5. The scheme of pBudCE4.1-LC3-GFP-RFP vector. GFP and RFP are coupled with 
LC3 under the CMV promoter.  
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2.2.2 Alkaline phosphatase staining 
Alkaline phosphatase is a highly expressed protein in pluripotent cells and its detection in 
cell colonies represents a strong evidence for the success of iPSC generation. In this study, 
alkaline phosphatase staining was performed according to the manufacturer’s instructions. 
Briefly, 1 ml sodium nitrite solution was first mixed with 1 ml FBB-alkaline solution for 
2 min, and then diluted in 45 ml H2O. Prior to the staining, the AS-BI alkaline solution 
was freshly added to the prepared mixture. The hiPSC cultures were washed twice with 
DPBS and fixed by citrate-acetone-formaldehyde solution at room temperature for 30 s. 
Then the cells were rinsed gently in H2O for 45 s. The alkaline-dye mixed solution was 
added and incubated for 15 min in the dark. Finally, the cells were washed with H2O and 
left to dry at room temperature. The positive cells were stained in red and the images 
were taken with the Zeiss microscope.  
2.2.3 Teratoma formation and analysis 
The hiPSCs cultured on feeder layer were used for the teratoma formation in vivo. 
Vici-iPSCs were dissociated in collagenase IV for 2-3 min before mechanically dissection 
into small clusters using a cell scraper. These clusters were collected with 2 ml hES 
medium and subcutaneously injected into the immunodeficient mice without 




). Teratomas were collected 60 
days after injection of iPSCs and fixed with phosphate buffered formalin (pH 7.0) for 4 h 
at room temperature. After washing with DPBS and H2O, the teratomas were dehydrated 
and embedded in paraffin using the Benchtop Tissue Processor 1020. Thereafter, the 
samples were sectioned into 6 μm sections with a microtome and subjected to histological 
staining with hematoxylin and eosin (H&E). The animal and histological experiments 
were performed by the technicians in Dr. Guan’s lab. All H&E images were obtained with 
brightfield microscopy.   
2.2.4 Isolation of genomic DNA and DNA sequencing  
Genomic DNA from hiPSCs was extracted using the automatic Maxwell 16 cell DNA 
purification kit under the manufacturer’s instructions. The cell pellets were suspended in 
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300 μl H2O and transferred into well 1 of the cartridge while the plunger was placed in 
well 7 of the cartridge. These cartridges containing samples and plungers were transferred 
onto the Maxwell 16 platform. The protocol for cells was then chosen and purification 
based on the magnetic sorting was activated. The DNA was eluted with 300 μl TE buffer. 
Concentration of the genomic DNA was measured at 260/280 nm using the NanoDrop 
2000 spectrophotometer. The isolated DNA was stored in the -80°C freezer.  
 
For the DNA sequencing, the specific regions of EPG5 were amplified by PCR from the 
genomic DNA using the specific primer sets. To verify the mutation in the generated 
Vici-iPSCs, the primer set EPG5_2 (see section 2.1.1) was used. To determine whether 
the homologous recombination happened in the genome of Vici-iPSCs after nucleofection 
with the CRISPR/Cas9-GFP plasmid and single-stranded oligonucleotides of EPG5, the 
primer set EPG5_3 (see section 2.1.1) was used. The PCR product was 
electrophoretically separated on a 1.5% agar gel, subsequently excised with a scalpel and 
extracted using the QIAquick gel extraction kit according to the manufacturer’s 
instructions. The isolated PCR product was then sent for DNA sequencing. 
2.2.5 Gene expression analysis 
2.2.5.1 Isolation of RNA from cultured cells 
Total RNA was isolated using the SV total RNA isolation system according to the 
manufacturer’s instructions. First, cells were lysed in 400-1000 μl RNA lysis buffer and 
transferred to a new Eppendorf tube where 400 μl of ethanol was added to precipitate the 
DNA. Then, 800 μl mixture was pipetted into a spin column and spun at 16100 x g for 1 
min in a centrifuge. 800 μl RNA washing buffer was added into the column and spun for 
an additional 1 min. The samples were treated with a mixture of supplied core buffer (45 
μl), 0.09 M MnCl2 (5 μl) and deoxyribonuclease I (DNase I, 5 μl) at room temperature 
for 15 min. After 200 μl DNase stop solution was added, the samples were spun and 
washed twice with the provided rinsing buffer. Thereafter, the RNA was eluted with 
nuclease-free H2O and stored at -80°C. The concentration of RNA was measured using 
the NanoDrop 2000 spectrophotometer at A260/A280. The isolated RNA was 
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subsequently used for reverse transcription.  
2.2.5.2 Reverse transcription of RNA to cDNA 
200 ng isolated RNA was used to synthesize complementary DNA (cDNA) with reverse 
transcriptase. The reagents were listed in the following table.  
Reagents Volume (20 μl in total) 
DEPC water and RNA 10.2 l 
10 x PCR buffer II 2 μl 
25 mM MgCl2 4 μl 
10 mM dNTPs 0.8 μl 
50 μM Oligo d(T)16 1 μl 
RNase inhibitor (20 U/μl) 1 μl 
MuL V reverse transcriptase (50 U/μl) 1 μl 
Reverse transcription was performed in a PCR cycler. The mixture was subjected to a 
cycle of thermal gradient of 22°C for 10 min, 42°C for 50 min, 99°C for 10 min and a 
cooling phase at 4°C. The resultant cDNA was then stored at -20°C for further usage. 
2.2.5.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify the specific DNA fragments. The 
traditional PCR reaction consists of denaturing of DNA strands, annealing of the forward 
and reverse primers and synthesis of DNA. The annealing temperature was determined 
with the primers of selected genes (2.1.1). The reagents were listed in the following table.  
Reagents Volume (25 μl in total) 
cDNA 1 μl 
10x Green GoTaq reaction PCR buffer 2.5 μl 
10 mM dNTPs 1 μl 
Forward primer (100 M) 1 μl 
Reverse primer (100 M) 1 μl 
GoTaq DNA polymerase (5 U/l) 0.1 μl 
DEPC water 18.4 μl 
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The PCR product was verified using gel electrophoresis on a 1.5% DNA agar gel.  
2.2.5.4 Agar gel electrophoresis 
The DNA fragments amplified by PCR were loaded in a 1-2% DNA agar gel and 
subjected to gel electrophoresis. The percentage of the gel was chosen depending on the 
size of the PCR product of the selected gene region. Briefly, agar was weighed and 
dissolved in 1x TB buffer. The agar was melted and allowed to cool gradually until 60°C. 
In order to visualize the amplified PCR bands under ultraviolet (UV) light, ethidium 
bromide was added before the agar mixture was poured into horizontal gel chamber with 
appropriate number of gel combs. The agar gel was polymerized after 20 min. Thereafter 
the amplified PCR products as well as the DNA molecular weight marker were loaded 
into the wells of the agar block. The gel was subjected to an electrophoresis of 70-120 
volts for 20-40 min. DNA bands were detected and characterized under UV 
trans-illumination and the images were captured using the Alpha image software. 
2.2.6 Western blot 
2.2.6.1 SDS polyacrylamide gel electrophoresis  
SDS polyacrylamide gel electrophoresis (PAGE) was used to separate proteins with 
different molecular weights. The 4%-20% ladder commercial SDS gels were purchased 
from Bio-Rad. Gels were assembled into the Bio-Rad chambers before immersing into 
the SDS running buffers. The samples with lysis buffer and pre-stain protein markers 
were loaded on the gel. The gels were then subjected to gel electrophoresis that runs at 70 
volts for 20 min and a further 1-1.5 h at 120 volts. The protein bands were then identified 
based on the expected size compared with the protein ladders. The gels were 
95 °C   3 min 
95 °C   30 s 
50-60 °C 30 s     
72 °C   30 s 
72 °C   10 min 
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counterstained with coomassie dye staining or used for further investigation of Western 
blot.  
2.2.6.2 Protein transfer and detection 
The proteins on the SDS-PAGE were electrophoretically transferred onto a PVDF 
membrane at 400 mA for 1 h in the blotting chamber filled with the transferring buffer 
and cooled with ice. The successfully transferred membrane was then washed three times 
with TBST buffer and subsequently treated with 5% non-fat dried milk for 1 h to block 
any unspecific binding. Primary antibody was diluted with 5% non-fat dried milk and 
overlaid onto the membrane and incubated at 4°C overnight. Thereafter, the membrane 
was washed with TBST buffer for 5 times at 5 min per rinse. The HRP-coupled 
secondary antibody was then overlaid onto the membrane and incubated at room 
temperature for 1 h. Following repeated washing steps of the membrane, the blots were 
incubated with detection buffer (ECL prime) for chemiluminescent signal recording. The 
detection buffer A and B were mixed at a ratio of 1:1 and layered over the membrane to 
allow for the signal development. Exposure and images of the developed membrane blots 
were recorded using VersaDoc coupled with ImageLab 5 software. All washing steps 
were performed at room temperature. 
2.2.7 Immunofluorescence staining and analysis of images 
For immunofluorescence staining, cells were fixed with 4% PFA for 20 min at room 
temperature. Thereafter, cells were washed with DPBS 3 times to remove traces of the 
fixative. The cells were then blocked with 1% BSA for 30 min at room temperature. For 
target antigens located in the cytoplasm and nuclei, the cells were permeabilized with 0.1% 
Triton X100 for 10 min. After washing with DPBS for 3 times, the primary antibody was 
diluted in 1% BSA and then incubated at 4°C overnight. The next day, cells were washed 
with DPBS for 3 times. The fluorescence dye-coupled secondary antibody was applied to 
the cells and incubated for 1 h at room temperature in the dark. The nucleus was 
counter-stained with 300 nM DAPI (1:2000 v/v dilutions from the 0.6 mM stock) for 15 
min at room temperature. Thereafter, the antibody-labeled samples were washed with 
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DPBS for 3 times and mounted onto glass slides with Fluoromount GM. Images were 
captured by using the confocal microscope. Brightfield images were also captured and 
used as indicated in corresponding figures.  
2.2.7.1 Measurement of cell surface in hiPSC-CMs  
Images of randomly selected ACTININ-stained cardiomyocytes were captured for cell 
surface measurement. The circumference of the stained cells was outlined manually and 
the cell surface area was automatically measured by using the Carl Zeiss AxioVision Rel 
4.8 software.  
2.2.7.2 Analysis of sarcomere length and organization in hiPSC-CMs 
For analysis of sarcomere length and organization of the sarcomere structures, the images 
of ACTININ-stained cardiomyocytes were analyzed using the Image J software as 
published previously (Weiwad et al., 2000).  
 
Before the analysis, the pixels of the images were converted into μm depending on the 
microscope settings. For the images used in this experiment were taken with 63 x oil lens 
with a spatial resolution of 0.102 µm/pixel. The regular sarcomere region including at 
least 8 sarcomeres was chosen. After the chosen images were determined, the distance 
between the first and second peak was recorded, representing individual sarcomere 
lengths.  
 
For analysis of sarcomeric organization, the observed striations aligned vertically in the 
field of view (FOV) were selected for further analysis. Two-dimensional fast Fourier 
transform (FFT) was processed on the selected region. Through FFT, the spatial domain 
of the intensity traces was transformed to the frequency domain (shown as radial profiles). 
Then the one-dimensional representation was calculated by plotting the radial profiles. 
The amplitude of the first peak represents the regularity of sarcomere structure in one 
direction, as the organization increases as more sarcomeric α‐ACTININ‐positive elements 
are localized regularly at a distance of the sarcomere length. The full width at half 
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maximum (FWHM) of the first-order line is a measure of the inhomogeneity of the 
sarcomere length (Figure 6).  
 
Figure 6. The scheme of quantitation of sarcomere structure. The sarcomere organization of 
-ACTININ stained cardiomyocytes was analyzed by FFT, scale bar: 20 m.  
2.2.8 Flow cytometry and cell sorting   
Flow cytometry analysis was used to analyze the purity of cardiomyocytes by using BD 
FACSCantoII. The cells were digested with 0.25% trypsin into single cells and spun in a 
centrifuge. The resulting cell pellet was washed with DPBS twice and then fixed with 4% 
PFA for 20 min at room temperature. After washing 3 times with DPBS, the cells were 
blocked and permeabilized in 1% BSA with 0.1% Triton X100 for 10 min. The cells were 
then incubated with the primary antibody for 30 min at 37°C. After removing the primary 
antibody by DPBS washing, fluorescence dye-coupled secondary antibody was applied 
and incubated for 30 min at 37°C. After washing with DPBS, the cell pellets were spun 
down and suspended in 200 μl DPBS and transferred into the 5-ml FACS tube. For flow 
cytometer analysis, the 10,000 total events were included. The results were analyzed by 
Flowing software.  
 
For cell sorting, hiPSCs that were transfected with CRISPR/Cas9 plasmid DNA were 
digested with TrypLE Express for 5 min at room temperature. The cell pellets were first 
sorted using a 25-m cell strainer, suspended in DMEM/F12 without phenol red and 
transferred into the 5-ml FACS tube. Single hiPSC was then sorted into the 
Geltrex-coated 96-well plates in E-8 medium using BD FACSAria II.  
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2.2.9 Cell volume analysis 
The cell volumes of cardiomyocytes were analyzed during flow cytometry analysis. Flow 
cytometry analysis was performed as described before and further analysis of 
forward-scattered light (FSC), which represents the cell volume of digested 
cardiomyocytes, was performed with the Flowing software (Figure 7).  
 
 
Figure 7. Analysis of cardiomyocyte volume using flow cytometry. The cTNT-positive 
cardiomyocytes were analyzed with the FSC. 
2.2.10 Cleavage assay 
To determine the cleavage efficacy of the designed sgRNA, HEK293T cells were first 
transfected with CRISPR/Cas9-GFP plasmid DNA. Briefly, the HEK 293T cells were 
passaged and cultured until 60% confluence before transfection. The cells were 
transfected with CRISPR/Cas9-GFP for 48 h according to the manufacturer’s instructions 
of TransIT-293 reagent. Genomic DNA was then extracted from the transfected and 
non-transfected cells. PCR was performed using the EPG5_3 primer set (2.1.1) according 
to the protocol provided in the genomic cleavage detection kit. The positive control 
provided in the kit was included. The PCR product was then denatured and re-annealed to 
produce heteroduplex mismatches. These mismatches were recognized and cut by the 
detection enzyme provided in the kit. The cleavage PCR product was detected and 
quantified using 1% agarose gel.   
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2.2.11 Engineered heart muscle   
2.2.11.1 Generation of engineered heart muscle  
In this study, EHMs were generated based on the published protocol (Soong et al., 2012). 
Briefly, hiPSC-derived cardiomyocyte cultures were dissociated into single 
cardiomyocytes using a mixture of 2.5% trypsin (0.25%), accutase (97.75%) and 1 mg/ml 
DNAase (2%). Non-myocytes that provide tissue support such as human foreskin 
fibroblasts were also concurrently dissociated with TrypLE Express at 37°C for 3 min. 
Together, the cell mixture containing single cardiomyocytes and fibroblasts with a ratio 
of 3:1 were mixed with the reagents as listed in the table below. 450 μl of the total master 
mix was transferred on individual casting mold recesses and incubated at 37°C for 1 h. 
Complete medium was then layered over the EHMs and allowed to incubate till tissue 
compaction. Culture medium was exchanged daily. After 72 h, the EHMs were manually 
transferred onto silicone poles to induce mechanical stretch. Medium was changed every 
2 days until day 14. The EHMs were then removed from the poles and subjected to force 
measurements in thermostatted organ baths.  
Total volume 2100 μl 
Cell suspension (1.5x10
6 
per EHM) 829 μl 
2x DMEM 535 μl 
NaOH 0.1 N 95 μl 
Matrigel 200 μl 
Rat collagen (3.2 mg/ml) 440 μl 
Number of EHMs 4 
2.2.11.2 Force measurement of engineered heart muscle 
Force measurement studies were carried out in thermostatted organ baths. Briefly, EHMs 
were carefully removed from the poles and placed onto the attached hooks on the force 
transducer. The organ baths were then filled with Tyrode buffer at 37
o
C. EHMs were then 
field stimulated at 2 Hz and manually stretched to allow for maximum force production. 
Thereafter, EHMs were subjected to increasing calcium concentration (0.2-4 mM) to 
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determine their calcium response and twitch forces were recorded using BMON software 
(FMI GmBH, Germany).  
2.2.11.3 Cell size measurement of CMs in EHMs 
Before the generation of EHMs, the diameters of cardiomyocytes were analyzed by using 
the Casy cell counter. Briefly, cardiomyocytes were dissociated into single cells as 
mentioned before. After the hEHM medium was added to neutralize trypsin, the cell 
pellets were spun down at 200 x g for 5 min. The pellets were re-suspended in 1 ml 
hEHM medium. According to the manufacturer’s instructions, 1 l cell suspension was 
diluted 20 times with H2O. Finally, based on the non-invasive electrical current exclusion 
principle, the diameters of the cardiomyocytes were automatically analyzed by using the 
Casy cell counter. 
2.3 Statistics 
All experimental data is presented as mean ± standard error of the mean (SEM). For two 
data sets, unpaired Student’s t-test was used. For more than two variables, analysis was 
performed using a two-way repeated analysis of variance (ANOVA) test. Statistically 
significance is presented as p<0.05 (*), p<0.01 (**) and p<0.001 (***). All statistical 




3.1 Generation of Vici-iPSCs and proof of pluripotency 
3.1.1 Generation of hiPSCs from the patient with Vici syndrome  
For the generation of Vici-iPSCs, fibroblasts derived from the patient with Vici syndrome 
were reprogrammed into hiPSCs through STEMCCA lentivirus transduction, which 
contains the transcription factors OCT4, SOX2, KLF4 and c-MYC in a single polycistronic 
vector. Because the proliferation rate of fibroblasts derived from this patient was quite slow, 
6x10
4
 fibroblasts at passage 3 in a well of a 12-well plate were transduced with STEMCCA 
virus for 24 h in the presence of 1 μg/ml polybrene (Figure 8). The transduced fibroblasts 
were cultured in HFBM with 10 ng/ml bFGF for 7 days and then passaged into 
Geltrex-coated dishes. E-8 medium with additional 10 ng/ml bFGF was applied to the 
culture 24 h later and used until iPSC colonies were observed. Colonies with the typical 
morphology of human pluripotent stem cells (tightly packed, sharp-edged, flat and high 
nuclear-cytoplasmic ratio) were picked at 30-40 days after transduction and further 
expended to establish the stable cell lines.  
 
Figure 8. The scheme of iPSC generation from fibroblasts derived from the patient with Vici 
syndrome.  
 
In total, five independent iPSC lines were established and three of them, named as iVici1.2, 
iVici1.3 and iVici1.5, were used for further pluripotency characterization. They were 
cultured on Geltrex-coated dishes in E-8 medium and showed typical morphology of 
human pluripotent stem cells (Figure 9A-C). Alkaline phosphatase staining as the first 
marker of successful reprogramming was performed at passage 6. The results showed that 
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the three analyzed iPSC lines were positive for alkaline phosphatase (Figure 9D-F).  
 
 
Figure 9. Alkaline phosphatase staining in Vici-iPSCs. The established Vici-iPSCs at passage 6 
(A-C) were positive for alkaline phosphatase activity (D-E). Scale bar: 50 m. 
3.1.2 Expression of pluripotent-related markers in Vici-iPSCs 
To investigate the pluripotency of Vici-iPSCs, pluripotent-related genes were analyzed by 
semi-quantitative RT-PCR (Figure 10). During cellular reprogramming, endogenous 
pluripotent-related genes were upregulated. The results showed that GDF3, FOXD3, 




Figure 10. Expression of pluripotent-related genes in Vici-iPSCs. The pluripotent genes GDF3, 
FOXD3, LIN28 and SOX2 were expressed in the three analyzed Vici-iPSC lines. The fibroblasts 
derived from the patient were used as negative control whereas the RNA isolated from human 
embryonic stem cells (hESCs) was used as positive control. 
Results 
 57 
Expression of the pluripotent-related markers was also confirmed in all analyzed 
Vici-iPSC lines by immunofluorescence staining with primary antibodies against OCT4, 
SOX2, NANOG, LIN28 and SSEA4 (Figure 11). Transcription factors OCT4, SOX2 and 
NANOG were located in the nuclei. LIN28, a RNA-binding protein, which acts as a 
posttranscriptional regulator of genes involved in developmental timing and self-renewal 
of stem cells, was located in the cytoplasm. SSEA4 as an early embryonic glycolipid 
antigen was located on the cell surface.  
 
Figure 11. Expression of pluripotent-related proteins in Vici-iPSCs. All three analyzed 
Vici-iPSC lines highly expressed pluripotent markers OCT4 (A-C, red), SOX2 (D-F, red), 
NANOG (G-I, red), LIN28 (J-L, red) and SSEA4 (M-O, green). Cell nucleus was stained with 
DAPI (blue). Scale bar: 50 m. 
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3.1.3 Spontaneous differentiation of Vici-iPSCs in vitro and in vivo 
Pluripotency of Vici-iPSCs was assessed by both in vitro and in vivo spontaneous 
differentiation via EB formation and teratoma generation, respectively. For in vitro 
differentiation, Vici-iPSCs were cultivated in suspension for 8 days in Iscove medium to 
form three-dimensional cell aggregates, so called EBs, which were then plated onto 
gelatin-coated dishes for further differentiation until day 33. Upon the formation of EBs, 
all analyzed Vici-iPSC lines started to differentiate spontaneously. Cells representing all 
three germ layers were found in EB outgrowths at day 33 as demonstrated by the positive 
staining by using antibodies against AFP suggesting endodermal development, SMA 
indicating mesodermal development and β-III-TUBULIN, a marker for neuroectodermal 
development (Figure 12). 
 
Figure 12. Spontaneous differentiation of Vici-iPSCs in vitro. Vici-iPSCs spontaneously 
differentiated into cells from all three germ layers via EB formation. Immunofluorescence 
staining results showed that the representative markers of endoderm AFP (A-C, green), 
mesoderm SMA (D-F, red) and neuroectoderm β-III-TUBULIN (G-I, green) were expressed in 
cells differentiated from iVici1.2, iVici1.3 and iVici1.5 cells. Cell nucleus was stained with DAPI 
(blue). Scale bar: 50 m. 
 
To study the in vivo teratoma development potential of the iPSCs, Vici-iPSCs (9x10
6
 cells 
per mouse) were subcutaneously injected into immunodeficient mice (n=2 for each cell 
line). Only iVici1.3 cells showed teratoma formation at day 59 after inoculation of the cells. 
The teratomas were dissected and processed with standard H&E staining. Histological 
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analysis of the sections showed that the teratomas were composed of derivatives of three 
embryonic germ layers (Figure 13).  
 
 
Figure 13. H&E staining of teratoma generated from iVici1.3 cells in vivo. The teratoma 
contained derivatives of three embryonic germ layers: epithelium (endoderm, A), muscle 
structure (mesoderm, B) and neural-like tissue (ectoderm, C). Scale bar: 50 m. 
3.1.4 Verification of EPG5 mutation in Vici-iPSCs 
Previous study showed that the patient with Vici syndrome carried a single nucleotide 
mutation site in EPG5 (c. 4952+1G>A) (Cullup et al., 2013), from whom the three 
Vici-iPSC lines iVici1.2, iVici1.3 and iVici1.5 were generated. To prove whether the 
mutation was kept in these three Vici-iPSC lines, genomic DNA sequencing was 
performed using the primer set EPG5_2 as shown in Figure 14A as F1 and R1. The 
sequencing results confirmed that the homogeneous mutation site (c.4952+1G>A) was 





Figure 14. Verification of the 
EPG5 mutation in the genome 
of Vici-iPSCs. 
Primers F1 and R1 were used to 
amplify the region containing 
the mutation site in genomic 
DNA (A). The EPG5 mutation 
(c.4952+1G>A) retained in 
Vici-iPSCs after cellular 
reprogramming was confirmed 






The mutation in EPG5 (c.4952+1G>A) occurs within the splice site between exon 28 and 
29 (Figure 14A), which may disrupt the mRNA splicing. Exome sequencing predicted 
that this mutation in EPG5 caused the exon 28 missing (Cullup et al., 2013) and resulted in 
a premature stop codon in exon 29. Further analysis on the cDNA level with the primer set 
EPG5_1 (2.1.1) as shown in Figure 15A as F2 and R2 showed that EPG5 mRNA transcript 
was 100 bp nucleotides shorter in Vici-iPSCs comparing with the Ctr-iPSCs (Figure 15 B). 
 
 
Figure 15. Verification of EPG5 mutation on mRNA level in Vici-iPSCs. The shorter product 
of EPG5 on mRNA level was seen in Vici-iPSCs compared with Ctr-iPSCs by RT-PCR (B) using 
the primer set F2 and R2 (A). 
 
Taken together, all three analyzed Vici-iPSC lines iVici1.2, iVici1.3 and iVici1.5 showed 
the typical morphology of human pluripotent stem cells, were positive for ALP, expressed 
pluripotent-related markers demonstrated by the RT-PCR analysis and 
immunofluorescence staining, and exhibited in vitro and in vivo differentiation potential. 
These data demonstrate that the generated and analyzed Vici-iPSC lines are pluripotent. 
Furthermore, the EPG5 mutation was verified in all three analyzed Vici-iPSC lines. 
3.2 Generation and phenotype analysis of Vici-iPSCs-derived cardiomyocytes  
3.2.1 Differentiation of cardiomyocytes from Ctr-iPSCs and Vici-iPSCs 
Cardiomyocytes derived from the iPSCs were generated through modifying the Wnt 
pathway by the GSK3 inhibitor CHIR99021 and the Wnt inhibitor IWP2 (Figure 16). 
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After 1 day of CHIR99021 exposure, hiPSCs differentiated into mesendoderm progenitor 
cells, which have the capacity to develop into muscle cells. After further 2 days of IWP2 
exposure, these mesodermal progenitor cells became committed towards cardiomyocyte 
specification. First beating cardiomyocytes were observed between day 8 and 12. As cell 
seeding densities and concentration of CHIR99021 directly influenced the yield of 
cardiomyocytes from the differentiation, the protocol was adapted and optimized to 
different iPSC lines. The control iPSC lines isWT1BLD2 (Ctr1), WTD2 (Ctr2), iBM76.3 
(Ctr3) and Vici-iPSC lines iVici1.2, iVici1.3, and iVici1.5 were differentiated into 
functional cardiomyocytes. Subsequent experiments mostly used the Ctr1, 2 and iVici1.2 
and iVici1.3 derived cardiomyocytes following culture for 2-3 months.  
 
Figure 16. Direct differentiation of hiPSCs into cardiomyocytes. The cardiomyocytes were 
differentiated according to the modified protocol (A). Brightfield images were captured and 
showed the typical density and morphology of hiPSCs during the differentiation on day 0, 2, 4, 8, 
12 and 60 (B). Scale bar: 50 m. 
 
In order to obtain pure population of cardiomyocytes, glucose was withdrawn from the 
differentiation medium and replaced by lactate to select metabolically active 
cardiomyocytes while reducing the population of non-cardiomyocytes. The cells were 
selected for 4-6 days. To determine the purity of cardiomyocytes following differentiation 
and selection, cells were harvested and incubated with antibody against cTNT. Results 
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from flow cytometry showed high purity of cardiomyocytes (appr. 90%), suggesting the 
differentiation and selection method is efficient in yielding pure cardiomyocytes (Figure 
17). The differentiation efficiency and CM purities of different Ctr- and Vici-iPSC lines 
showed no significant difference (Figure 17). 
 
 
Figure 17. Efficiency of direct differentiation of hiPSCs into cardiomyocytes. Flow cytometry 
analysis of cTNT-positive cells was performed after cultivation in cardiac culture medium 
(RPMI+B27) for 2-3 months. The results showed the efficiency of cardiac differentiation from 
Ctr-iPSCs and Vici-iPSCs. Ctr1: 94.57%; Ctr2: 96.86%; iVici1.2: 92.45%; iVici1.3: 83.2% and 
iVici1.5: 94.03%. 
 
Additionally, to confirm our observation of cardiomyogenesis from the differentiation 
protocol, gene expression of cardiac-specific markers using RT-PCR was investigated. The 
results showed that MYH7, MYL2, and genes encoding cardiac transcriptional factor 
NKX2.5 and sarcomeric structural components TNNT2 were highly expressed in 
cardiomyocytes derived from both Ctr-iPSCs and Vici-iPSCs compared to undifferentiated 
hiPSCs. There was no significant difference observed among different Ctr- and Vici-iPSC 





Figure 18. Gene expression of cardiac-related markers by RT-PCR. The RT-PCR analysis of 
cardiac-related genes MYH7, MYL2, NKX2.5 and TNNT2 was performed. These genes were 
highly expressed in both Ctr-iPSCs- and Vici-iPSCs-derived cardiomyocytes compared with 
undifferentiated iPSCs. 
 
Next, protein expression of cardiac-specific markers was analyzed by immunofluorescence 
staining. The results showed that cardiomyocytes derived from both Ctr- and Vici-iPSC 
lines expressed myofilament proteins such as cTNT, α-ACTININ and MLC2V. The gap 
junction protein CX43 was highly expressed and detected between adjacent 
cardiomyocytes derived from both Ctr- and Vici-iPSC lines (Figure 19). 
 
 
Figure 19. Structural characterization of Ctr- and Vici-iPSC-CMs. The cardiomyocytes were 
singularized and plated onto the Geltrex-coated coverslips. Immunofluorescence staining of 
α-ACTININ (A and B, green), cTNT (C and D, green) and MLC2V (E and F, red) showed the 
sarcomere organization. The gap junction protein CX43 was detected between adjacent cells (C 
and D, red). Cell nucleus was stained with DAPI (blue). Scale bar: 50 m. 
 
Altogether, purified cardiomyocytes that highly expressed the cardiac-related markers 
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including -ACTININ, MLC2V and cTNT can be obtained from both Ctr- and Vici-iPSCs 
with high efficiency using the differentiation protocol mentioned in this study. These 
functional beating cardiomyocytes were subsequently used for further phenotype analysis.  
3.2.2 Vici-iPSCs-CMs show larger cell surface area but normal cell volume 
In order to investigate if Vici-iPSC-CMs carry the hypertrophy phenotype in vitro, the cell 
surface area of both Ctr- and Vici-iPSC–CMs was measured. The cardiomyocytes were 
singularized after culturing for 2-3 months and stained with antibodies targeting 
sarcomeric α-ACTININ. Images of randomly selected single cardiomyocytes were 
captured and surface area was analyzed using AxioVision software based on the 
immunofluorescence staining (Figure 20A, B). The results showed that the average cell 
surface area of Vici-iPSC-CMs (Vici Nc: 4564 ± 692.8 m
2
) was significantly larger 
compared to Ctr-iPSC-CMs (Ctr Nc: 2226 ± 127.8 m
2
) under basal conditions (Figure 
20C).  
 
To rule out autophagy-induced hypertrophy of Vici-iPSC-CMs, cardiomyocytes were 
treated with the autophagy inducer rapamycin and blocker bafilomycin. Interestingly, 
despite DMSO, rapamycin and bafilomycin treatments, the cell surface areas of 
Vici-iPSC-CMs remain significantly larger than that of Ctr-iPSC-CMs (Figure 20C). 
There was no big difference among untreated (Nc), DMSO and drug treatment groups in 




Figure 20. Measurement of cell surface area of Ctr- and Vici-iPSC-CMs. The cell surface 
area was measured in CMs 10 days post dissociation after 3-month culture (A and B). The 
average cell surface area was bigger in Vici-iPSC-CMs compared with Ctr-iPSC-CMs under 
basal condition, DMSO, rapamycin and rapamycin with bafilomycin treatment (C). In total, the 
iPSC lines from control (Ctr1 and Ctr2) and Vici syndrome (iVici1.2, iVici1.3 and iVici1.5) were 
used. The mean area with SEM and cell number from each group is illustrated in the following: 
Ctr Nc: 2226 ± 128 (n=299); Ctr DMSO: 2245 ± 96 (n=302); Ctr Rap: 1903 ± 77 (n=301); Ctr 
Rap+BafA1: 2085 ± 106 (n=299); Vici Nc: 4564 ± 693 (n=381); Vici DMSO: 3409 ± 147 
(n=338); Vici Rap: 4112 ± 159 (n=358); Vici Rap+BafA1: 4023 ± 339 (n=368); unit, m
2
. Scale 
bar: 50 µm. 
 
Moreover, the volumes of cardiomyocytes were analyzed by flow cytometry analysis. Both 
Ctr- and Vici-iPSC-CMs were stained with antibody against the sarcomeric structural 
protein cTNT. The overlap histogram of FSC of the cTNT-positive cells demonstrated that 




Figure 21. FSC distribution of Ctr- and Vici-iPSC-CMs. No significant differences of cell 
volumes were observed between Ctr- (A and B) and Vici-iPSC-CMs (C, D, and E) as shown in 
the histogram overlap in FSC (F).  
3.2.3 Vici-iPSC-CMs exhibit multidirectional sarcomere organization but sarcomere 
lengths show no difference 
To evaluate the sarcomere length of hiPSC-CMs, the cardiomyocytes stained with 
α-ACTININ were analyzed with Image J. Similar sarcomere length was observed between 





Figure 22. Similar sarcomere length in Ctr- and Vici-iPSC-CMs. The immunostaining images 
using the antibody against α-ACTININ analyzed by Image J showed that there was no significant 
difference in the sarcomere length between Ctr- and Vici-iPSC-CMs.  
 
Although the sarcomere length showed no significant difference between Ctr- and 
Vici-iPSC-CMs, Vici-iPSC-CMs were observed with complicated sarcomere structure 
under the microscope after the immunofluorescence staining against α-ACTININ, a 
cardiac Z-disk component (Figure 23A and B). The sarcomere regularity analysis was 
carried out by the two-dimensional FFT. The amplitude of the first order peak showed no 
difference between Ctr- and Vici-iPSC-CMs, suggesting consistent regularity of 
sarcomeres in one direction (Figure 23D). The FWHM  of  the  first-order  peak was higher 
in Vici-iPSC-CMs compared with Ctr-iPSC-CMs, indicating the higher inhomogeneity of 
the sarcomere length in Vici-iPSC-CMs (Figure 23C). In addition, sarcomeres in 
Vici-iPSC-CMs distributed at different directions (Figure 23B). The α-ACTININ 
structure was crossly distributed in a multidirectional way in the Vici-iPSC-CMs in 





Figure 23. Quantitation of sarcomere organization of Ctr- and Vici-iPSC-CMs. The typical 
morphology of Ctr- and Vici-iPSC-CMs stained with α-ACTININ (A and B). The sarcomere 
structure in Vici-iPSC-CMs had a multidirectional distribution. The quantitation of FWHM (C) 
and peak amplitude (D) analyzed with two-dimensional FFT showed higher inhomogeneity of the 
sarcomere length in Vici-iPSC-CMs. Scale bar: 50 m. 
 
Taken together, Vici-iPSC-CMs were observed to exhibit a large cell surface area but 
minimal difference in cell volumes compared to Ctr-iPSC-CMs. Vici-iPSC-CMs showed 
normal sarcomere length but with a multidirectional distribution based on the analysis of 
the sarcomeric protein α-ACTININ.  
3.2.4 Functional analysis by generating engineered heart muscle 
On the basis of heightened multidirectional sarcomere structure in Vici-iPSC-CMs and to 
further investigate if autophagy defects can influence the functional contractility, EHMs 
were generated. Before used for the generation of EHMs, both Ctr- and Vici-iPSC-CMs 
were dissociated into single cells and the cell diameter was measured by using Roche Casy 
cell counter. The results showed no significant difference between Ctr-iPSC-CMs (20.51 ± 




Figure 24. Cell diameter of Ctr- and Vici-iPSC-CMs before used for generiation of EHMs. 
The Vici-iPSC-CMs showed similar cell diameter to Ctr-iPSC-CMs.  
 
EHMs generated from both Ctr- (Ctr-EHMs) and Vici-iPSC-CMs (Vici-EHMs) were 
stretched and further cultured for 2 weeks. Twitch tension of EHMs, expressed as force of 
contractions (FOC) in mN, was measured in a thermostatted organ bath (Figure 25A). 
Additionally, forces developed in EHMs were measured over a dose response exposure to 
calcium concentrations from 0.2 mM to 4 mM. The results revealed that the Vici-EHMs 
(n=14) developed similar contractile forces compared with Ctr-EHMs (n=15) (Figure 
25B). Interestingly, the FOC relative to the cross-sectional area (CSA) was higher in 
Vici-EHMs than in Ctr-EHMs (Figure 25C and D). In order to elucidate whether higher 
FOC/CSA observed in Vici-EHMs was attributed to the diseased cardiomyocytes, 
Ctrl-EHMs and Vici-EHMs were digested into single cells and cellular composition 
(cardiomyocytes and non-myocytes) was analyzed by flow cytometry. Cells were stained 
with cardiac Z-disk binding protein α-ACTININ on the day of measurement. The numbers 
of cardiomyocytes in EHMs were counted (Figure 25E) and the beating forces were 
calculated for a single cardiomyocyte. The data indicated that single cardiomyocytes in 
Vici-EHMs maintained the similar FOC to those in Ctr-EHMs (Figure 25F). In summary, 





Figure 25. Measurement of contractile forces of EHMs generated from Ctr- and 
Vici-iPSC-CMs. A thermostatted organ bath was used for the measurement (A). Vici-EHMs 
(n=14) showed similar absolute force of contractions (FOC) with extracellular calcium 
concentration compared with Ctr-EHMs (n=15) (B). The FOC per cross-sectional area (CSA) was 
higher in Vici-EHMs than in Ctr-EHMs (C and D) whereas the FOC per CM was similar in 
Vici-EHMs and Ctr-EHMs (E and F).  
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3.2.5 Autophagy defect in Vici-iPSC-CMs 
3.2.5.1 Accumulation of autophagy markers LC3 in Vici-iPSC-CMs 
To determine if cardiomyocytes show the autophagy defect, as observed in fibroblasts from 
the patient with Vici syndrome (Cullup et al., 2013), the expression levels of LC3, P62 and 
NBR1 were studied in Vici-iPSC-CMs compared to Ctr-iPSC-CMs by performing Western 
blot (Figure 26). The results indicated that untreated Vici-iPSC-CMs (Vici Nc) showed 
significantly increased expression levels of LC3 (LC3I and LC3II), in particular LC3II, the 
lipidated form of LC3, and slight increases of P62 and NBR1 in comparison to 
Ctr-iPSC-CMs (Ctr Nc). 
 
 
Figure 26. LC3I and LC3II were accumulated in Vici-iPSC-CMs. The autophagy adaptors 
P62 and NBR1 were only slightly accumulated whereas unprocessed LC3I and processed LC3II 
were significantly increased in untreated Vici-iPSC-CMs (n=5) in comparison to Ctr-iPSC-CMs 
(n=5). LC3 and the ratio of LC3II/I were increased after rapamycin and combined treatments in 
Ctr-iPSC-CMs. In contrast, no further accumulation of LC3I and LC3II was observed in 
Vici-iPSC-CMs after rapamycin and combined treatments (A and B). Following the rapamycin 
treatment, P62 and NBR1 were slightly elevated in Ctr-iPSC-CMs, but not in Vici-iPSC-CMs, 
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while the combined treatment led to a strong accumulation of these proteins in both Ctr- and 
Vici-iPSC-CMs (A, C and D). 
 
In order to determine if LC3, P62 and NBR1 levels are reflective of increased upstream 
induction and/or downstream blockade of autophagy, Ctr- and Vici-iPSC-CMs were 
treated with the autophagy inducer rapamycin (100 nM) and the autophagy blocker 
bafilomycin (200 nM) for 12 h. Rapamycin is one of the inhibitors of the mTORC1 
complex. Bafilomycin is an inhibitor of the autolysosomal H
+
 ATPase, which regulates the 
acidification and hence the degradation of proteins in lysosomes (Klionsky et al., 2012). In 
Ctr-iPSC-CMs, induction of autophagy by rapamycin led to slight accumulation of P62, 
NBR1 and LC3II/LC3I, while the combined upstream activation by rapamycin and the 
downstream blockade by bafilomycin resulted in further strong accumulation of these 
proteins (Figure 26A-D). In contrast, in Vici-iPSC-CMs, the expression levels of P62 and 
NBR1 were not further elevated following the rapamycin treatment, but enhanced after the 
combined treatment (Figure 26A, C, and D). Furthermore, the expression level of LC3 
(LC3I and LC3II) was also not further increased after the rapamycin treatment, or the 
combined treatment. The ratio of LC3II/I in Vici-iPSC-CMs was slightly, but not 
significantly increased following the rapamycin treatment, and the combined treatment 
(Figure 26A, B). This suggests that there is no impairment in the induction of early 
processes in autophagy, including the processing of LC3I to LC3II, but that the clearance 
of autophagosomal cargo is nearly saturated in Vici-iPSC-CMs.     
  
To further investigate the autophagy blockade in Vici syndrome, Ctr- and Vici-iPSC-CMs 
were exposed to the drugs of isoproterenol (100 nM) and phenylephrine (5 ) for 12 h 
and in combination of them with rapamycin and bafilomycin. Isoproterenol is a 
non-selective β-adrenergic receptor agonist, and primarily used to treat bradycardia or 
heart block through increasing the heart rate (American Heart, 2006). Phenylephrine is a 
selective α1-adrenergic receptor agonist and decreases the heart rate through increasing 
blood pressure (Antonopoulos et al., 2002). The hiPSC-CMs showed the same response 
(increased or decreased beating rate, respectively) to both drugs (data not shown). In 
Ctr-iPSC-CMs treated with isoproterenol, phenylephrine, or their combination, the 
autophagy markers LC3I, LC3II and P62 were significantly higher expressed following the 
combined upstream activation by rapamycin and the downstream blockade by bafilomycin, 




However, in Vici-iPSC-CMs after the isoproterenol, phenylephrine, or the combined 
treatment, strong baseline accumulation of the unprocessed LC3I and processed LC3II 
was observed without rapamycin, or bafilomycin treatments. More interestingly, in 
Vici-iPSC-CMs treated with isoproterenol or phenylephrine, the expression level of LC3 
(LC3I and LC3II), in particular LC3II, was further increased after the rapamycin treatment, 
or the combined treatment (Figure 27). Similar to Ctr-iPSC-CMs after the isoproterenol, 
phenylephrine, or the combined treatment, Vici-iPSC-CMs revealed marked accumulation 
of P62 after the dual induction of autophagy by rapamycin and block of autophagosomal 
degradation by bafilomycin (Figure 27).  
 
 
Figure 27. Enhanced expression of LC3 in Vici-iPSC-CMs after isoproterenol and 
phenylephrine stimulations. LC3I and LC3II were significantly accumulated in Vici-iPSC-CMs 
(n=2) after isoproterenol and phenylephrine stimulations compared with Ctr-iPSC-CMs (n=2) 
under basal, rapamycin and rapamycin and bafilomycin conditions.  
 
Altogether, as a widely used marker of autophagy pathway, the enhanced LC3I and LC3II 
accumulation and conversion between LC3I and LC3II under normal and isoproterenol or 
phenylephrine stimulation conditions suggest that the autophagosomes might be 
aggregated in the Vici-iPSC-CMs. 
3.2.5.2 Autophagosome accumulation in Vici-iPSC-CMs 
The increased ratio of LC3II/I was detected by Western blot, suggesting the accumulation 
of autophagosomes in Vici-iPSC-CMs. In order to assess this hypothesis, 
immunofluorescence staining with antibodies against LC3 was performed. The 
cardiomyocytes were also stained with the antibody against the sarcomere protein 
α-ACTININ. The analysis demonstrated that a low level of LC3II-positive puncta 
appeared in Ctr-iPSC-CMs. As expected, in the Vici-iPSC-CMs, there were numerous 
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LC3II-positive puncta, mostly located around the nuclei (Figure 28).  
 
 
Figure 28. Accumulation of LC3II-positive puncta in Vici-iPSC-CMs in vitro. 
Immunofluorescence staining revealed that LC3II-positive puncta (red) were accumulated in 
Vici-iPSC-CMs (E) compared with Ctr-iPSC-CMs (B) under the normal condition (without the 
induction of autophagy or the blockade of clearance). -ACTININ (A, C, green) was stained as a 
cardiomyocyte marker. Scale bar: 50 m. 
 
To further confirm that autophagosomes are accumulated in Vici-iPSC-CMs and to rule out 
possible artifacts of immunostaining, the untreated cardiomyocytes were transfected with 
the LC3-GFP-RFP sensor. By using this sensor, the amount of autophagosomes is 
correlated with the number and intensity of the co-localized red and green fluorescent 
puncta, which represent the association of LC3II with autophagosomes (Zhang, 2015). The 
results showed that a high level of numbers puncta with the co-localization of red and green 
fluorescence existed in Vici-iPSC-CMs at baseline (Figure 29), suggesting the LC3-II 
localization to the autophagosome. These data indicates that autophagosomes are 




Figure 29. Accumulation of LC3-GFP-RFP in untreated Vici-iPSC-CMs. The untreated 
cardiomyocytes were transfected with the LC3-GFP-RFP sensor. The strong co-localization of red 
and green fluorescence signal in Vici-iPSC-CMs (D-F) revealed the accumulated 
autophagosomes compared with Ctr-iPSC-CMs (A-C). Scale bar: 50 m. 
3.2.5.3 Abnormal localization of lysosomes in Vici-iPSC-CMs 
The lysosome is important for recycling and degrading proteins. Abnormalities of 
lysosomes can result in genetic diseases known as lysosome storage diseases. In previous 
study, the fibroblasts derived from the patient with Vici syndrome showed the fusion 
blockade of autophagosomes with lysosomes (Cullup et al., 2013). In order to determine 
the presence of lysosomes in the hiPSC-CMs, cardiomyocytes were stained with LAMP1. 
The results illustrated that the localization of LAMP1 between Ctr-iPSC-CMs and 
Vici-iPSC-CMs was totally different. In Ctr-iPSC-CMs, the LAMP1-positive puncta were 
mostly localized in the cytoplasm while only a small number were perinuclear (Figure 
30A-C). In Vici-iPSC-CMs, the number of LAMP1-positive puncta was reduced while the 
size of the puncta was increased. Surprisingly, there were distinct perinuclear puncta 
(Figure 30D-F). The different localization of LAMP1-positive puncta indicates the 
abnormal distribution of lysosomes in Vici-iPSC-CMs. These data also imply that EPG5 






Figure 30. Abnormal localization of lysosomes in Vici-iPSC-CMs. Immunofluorescence 
staining was performed against LAMP1 (red). The results demonstrated that a few large 
lysosomes were located around the nucleus in Vici-iPSC-CMs (E) while many small lysosomes 
were distributed throughout the cytoplasm in Ctr-iPSC-CMs (B). Phalloidin (green) was used to 
label F-ACTIN in the cardiomyocytes. Scale bar: 50 m. 
3.2.5.4 Fusion of autophagosomes with lysosomes was blocked in Vici-iPSC-CMs 
To study the fusion of autophagsomes with lysosomes, the cardiomyocytes were treated 
with autophagy inducer rapamycin and autophagy blocker bafilomycin for 12 h and were 
imaged after immunofluorescence staining of LC3 and LAMP1 (Figure 31). The LC3II- 
and LAMP1-positive puncta were significantly accumulated, and localized around the 
perinuclear region in both Ctr- and Vici-iPSC-CMs. In Ctr-iPSC-CMs, majority of the 
accumulated LC3II-positive puncta were found engulfed by the LAMP1-positive vesicular 
structures, suggesting that the autophagosomes were successfully fused with the lysosomes. 
In contrast, in Vici-iPSC-CMs, the co-localization of LAMP1-positive puncta with the 
LC3II-positive puncta was significantly reduced. Many LAMP1-positive vesicles without 
LC3II-positive puncta inside and many isolated LC3II-positive puncta were observed 
(Figure 31). These results indicate that there is impaired fusion of autophagosomes with 




Figure 31. Blocked fusion of LC3II-positive puncta with LAMP1-positive puncta in 
Vici-iPSC-CMs. The LC3II-positive puncta (green) were engulfed by the LAMP1-positive 
vesicles (red) in Ctr-iPSC-CMs (A-C), whereas numerous LAMP1-positive vesicles were 
detected without LC3II-positive puncta in Vici-iPSC-CMs (D-F). The cardiomyocytes were 
subjected to rapamycin and bafilomycin for 12 h. Scale bar: 50 m. 
3.2.5.5 Colocalization of autophagy adaptor P62 and NBR1 in Vici-iPSC-CMs 
Expression levels of the autophagy adaptor P62 and NBR1 were slightly changed in 
Vici-iPSC-CMs, as detected by Western blot analysis. To see whether the distributions of 
the cargo-recognition proteins P62 and NBR1 are altered in Vici-iPSC-CMs, 
cardiomyocytes treated with rapamycin and bafilomycin were used for 
immunofluorescence staining. The results showed that both P62 and NBR1 were 
accumulated in Ctr- and Vici-iPSC-CMs after the rapamycin and bafilomycin treatment. 
The co-localization of P62-positive puncta and NBR1-positive puncta in Vici-iPSC-CMs 
(Figure 32 D-F) were found with the similar frequency to those observed in 




Figure 32. Colocalization of P62 and NBR1. The autophagy cargo-recognition proteins P62 
(green) and NBR1 (red) were labeled in cardiomyocytes treated with rapamycin and bafilomycin. 
The accumulated P62 and NBR1 were visible in both Ctr-iPSC-CMs (A-C) and Vici-iPSC-CMs 
(D-F). P62 and NBR1 colocalized around the nucleus with the similar frequency in both cell 
types. Scale bar: 50 m. 
 
In addition, the staining of P62 and LAMP1 demonstrated that in Ctr-iPSC-CMs, 
P62-positive puncta were engulfted in LAMP1-positive puncta as the ring shaped 
structures. In Vici-iPSC-CMs, occasional fusion was observed in small P62-positive 
puncta and LAMP1-positive puncta. Many non-fused P62-positive puncta were observed 




Figure 33. P62-positive puncta fused with lysosomes. Immunofluorescence staining was 
performed after rapamycin and bafilomycin treatment. In control cells (A-C), P62 (green) fused 
with LAMP1 (red) as a ring-shaped structure. In patient cells (D-F), P62 fused with LAMP1 as 
small puncta and some non-fused P62 were observed. Scale bar: 50 m. 
 
Taken together, the expression and localization of P62 and NBR1 in the Ctr-iPSC-CMs and 
Vici-iPSC-CMs were similar indicating that the formation of autophagy cargo is normal in 
Vici-iPSC-CMs. The abnormal fusion of P62- and LAMP1-positive structures in 
Vici-iPSC-CMs suggests that the function of EPG5 is mostly involved in the fusion of 
autophagosomes with lysosomes.  
3.2.5.6 Mitochondrial localization in hiPSC-CMs 
Electron microscopy analysis of skeletal muscle biopsy from this patient showed variable 
size, abnormal distribution and morphology of mitochondria (Cullup et al., 2013). 
Mitochondria are important for cell survival by generating adenosine triphosphate (ATP). 
To compare the mitochondrial localization in Vici-iPSC-CMs with Ctr-iPSC-CMs, the 
cells were stained with the antibody against COXIV, which catalyzes the last step in 
electron transfer chain of the mitochondria. Preliminary data showed similar distribution of 
mitochondria in Ctr-iPSC-CMs and Vici-iPSC-CMs, as indicated by the similar 
localization of COXIV. In addition, COXIV-positive structures were not accumulated in 




Figure 34. Mitochondrial distribution in Ctr- and Vici-iPSC-CMs. The cardiomyocytes were 
stained with COXIV (green) and LAMP1 (red). There was no obvious accumulation of 
mitochondria in Vici-iPSC-CMs (D-F) compared with Ctr-iPSC-CMs (A-C). Scale bar: 50 m. 
 
In summary, these data illustrate a serious defect of autophagy in Vici-iPSC-CMs. 
Enhanced expression of LC3I and LC3II as well as numerous LC3II positive puncta were 
detected in the untreated Vici-iPSC-CMs demonstrated by Western blots and 
immunofluorescence staining. After the dual treatment with rapamycin and bafilomycin, 
empty lysosomes without any autophagy cargo were visible in the Vici-iPSC-CMs, shown 
by double stainging of LAMP1 and LC3 or LAMP1 and P62 in the cells. Furthermore, the 
abnormal localization of LAMP1-positive structures in Vici-iPSC-CMs suggests that 
EPG5 may be involved in the lysosome biogenesis and/or cellular trafficking. However, 
there is no obvious difference of the expression and localization of the autophagy adaptors 
P62 and NBR1. In addition, the distribution of mitochondria in Vici-iPSC-CMs is 
comparable to that in Ctr-iPSC-CMs. 
3.2.6 Abnormal AKT pathway in Vici-iPSC-CMs 
To determine if the abnormality observed in Vici-iPSC-CMs involves changes in the 
regulatory signal pathway of autophagy, the classical PI3K/AKT/mTOR/ pathway was 
elucidated in this study. This pathway regulates many cellular processes such as cellular 
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metabolism, cell proliferation, cell growth, survival, apoptosis, gene transcription, protein 
synthesis and so on. It controls the expression of autophagy proteins by inhibiting the 
transcriptional activity of FoxO transcription factors (Daitoku et al., 2011). 
 
First, the investigation of phosphorylation of AKT showed significantly reduced 
phosphorylation of two activating sites of AKT (AKT S473 and AKT T308) in both 
untreated and treated (rapamycin, rapamycin with bafilomycin) Vici-iPSC-CMs in 
comparison to those in Ctr-iPSC-CMs (Figure 35). 
 
 
Figure 35. Reduced phosphorylation of AKT S473 and AKT T308 in Vici-iPSC-CMs. 
Phosphorylation of two activating sites of AKT serine 473 (S473) and threonine 308 (T308) were 
reduced in Vici-iPSC-CMs under basal conditions, rapamycin treatment, and combined treatment 
with rapamycin and bafilomycin.  
 
Second, phosphorylation of the downstream proteins of AKT including FOXO3 and 
FOXO1 were assessed. The phosphorylation of activating sites of FOXO3 (FOXO3 T32) 
and FOXO1 (FOXO1 T24) were also dramatically decreased in both treated and untreated 
(rapamycin, rapamycin with bafilomycin) Vici-iPSC-CMs compared to Ctr- iPSC-CMs 




Figure 36. Decreased phosphorylation of FOXO3 threonine 32 (T32) and FOXO1 threonine 
24 (T24) in Vici-iPSC-CMs.  
 
In addition, the analysis of total and phosphorylation of mTOR protein was performed. The 
data showed that treatments with rapamycin or rapamycin and bafilomycin resulted in 
decrease of total mTOR and mTOR S2448 phosphorylation in Ctr-iPSC-CMs, as expected 
(Figure 37). In Vici-iPSC-CMs, marked baseline reduction of total mTOR and mTOR 
S2448 phosphorylation compared to Ctr-iPSC-CMs was observed. Treatments with 
rapamycin or rapamycin and bafilomycin led to further slight reduction of mTOR S2448 
phosphorylation (Figure 37).  
 
 
Figure 37. mTOR expression and phosphorylation in Vici-iPSC-CMs. In both control and 
patient cells, the expression of total mTOR and phosphorylation of mTOR (S2448) were reduced 
after rapamycin, or rapamycin and bafilomycin dual treatment. In addition, the total mTOR and 
mTOR S2448 were reduced under basal condition in Vici-iPSC-CMs compared with 
Ctr-iPSC-CMs. 
 
Moreover, P70S6K, which is one of the direct downstream regulatory proteins of mTOR, 
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was analyzed. The results demonstrated that the expression and phosphorylation (T389) of 
P70S6K was similar in untreated Vici-iPSC-CMs and Ctr-iPSC-CMs (Figure 38). The low 
phosphorylation of P70S6K was not observed after rapamycin treatment or dual treatment 
with rapamycin and bafilomycin in both Ctr- and Vici-iPSC-CMs. 
 
 
Figure 38. Phosphorylation of P70S6K in Ctr-iPSC-CMs and Vici-iPSC-CMs. The 
assessment of phosphorylation of P70S6K threonine 389 (T389), a direct downstream target of 
mTOR, showed similar expression in both Ctr-iPSC-CMs and Vici-iPSC-CMs. 
 
Furthermore, the preliminary analysis of GSK3 showed that total expression of GSK3 
and phosphorylation of GSK3 S21/9 seemed to be similar in both Ctr- and 
Vici-iPSC-CMs (Figure 39).  
 
Figure 39. Phosphorylation of GSK3 in Ctr- and Vici-iPSC-CMs. The expression of total 
GSK3 and phosphorylation of GSK3 at two activating sites serine 21 and 9 (GSK3 S21/9) 
seemed to be no significant difference between Ctr- and Vici-iPSC-CMs. 
 
In summary, the abnormalities of the AKT/mTOR classic pathway including reduced 
phosphorylation of AKT T308, AKT S473, FOXO3 T32, FOXO1 T24, and mTOR S2448 
were found in Vici-iPSC-CMs compared to Ctr-iPSC-CMs. Base on the preliminary data, 
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no big differences of the expression and phosphorylation of P70S6K and GSK3were 
found in Ctr- and Vici-iPSC-CMs The irregular regulation, in particular phosphorylation 
of AKT may not only cause the autophagy defect in Vici-iPSC-CMs but also lead to other 
multiple dysfunctions in EPG5 mutant cardiomyocytes. However, it is still unknown if the 
EPG5 mutation was the only causative factor for the abnormal phenotypes observed in 
Vici-iPSC-CMs. 
3.3 Gene editing by CRISPR/Cas9 technology 
To determine that the abnormalities of sarcomere structure and autophagy defects in 
Vici-iPSC-CMs was only due to the EPG5 mutation, oligonucleotide-based gene editing 
via the CRISPR/Cas9 technology was applied to “rectify” the mutation in the EPG5 gene 
in Vici-iPSCs. Initially, targeting sgRNA nearby the mutation site in EPG5 
(c.4952+1G>A) were designed. The computational prediction of potential off-target sites 
of Cas9 were performed (by Sigma). Only one EPG5 sgRNA (Figure 40A) at 34 bp 
before the EPG5 mutation site was found free of off-target with up to n=2 mismatches. 
This sgRNA was then cloned into the CRISPR/Cas9 system. 
 
The 150 bp-long single-stranded oligonucleotides of EPG5 as donor templates (Figure 
40A) were designed and used to replace the mutation site through homologous 
recombination. In the donor oligonucleotides, 6 synonymous substitutions were made in 
the region of protospacer adjacent motif (PAM) and sgRNA binding sites to prevent donor 
DNA from cleavage by Cas9 in the edited hiPSCs, and to aid the distinction between the 
donor and wild-type sequences, respectively. The synonymous substitutions resulted in 
the introduction of a new restriction enzyme site Hind III in the sgRNA. Afterwards, the 
mutated nucleotide was also changed from adenine (A) to guanine (G). Then, a stepwise 
protocol was established to edit EPG5 in Vici-iPSCs (Figure 40B). Briefly, first, the 
CRISPR/Cas9-GFP plasmid was transfected into HEK293T cells and the cleavage assay 
was used to determine the efficiency of the CRISPR/Cas9 system. Second, the 
CRISPR/Cas9 cassette was transfected using nucleofection into Vici-iPSCs and single 
living GFP-positive cells were sorted. Thereafter, sorted GFP
+ 
single Vici-iPSCs were 
cultured until sufficient pure colonies available and genomic DNA from these colonies was 
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extracted for sequencing.  
 
 
Figure 40. The scheme of correcting the mutation in EPG5 by using the CRISPR/Cas9 
technology. The PAM motif and sgRNA was chosen 31bp and 34bp before the point mutation 
(green), respectively. The oligonucleotides with the corrected point mutation and synonymous 
mutations were synthesized (red) (A). The flowchart of the technique was shown in B. 
 
After the CRISPR/Cas9-GFP vector was transfected into HEK293T cells, GFP
+ 
cells were 
observed 48 h later (Figure 41A, B). The efficiency of successful CRISPR/Cas9 editing, 
recognizing and cutting the target DNA was analyzed using enzymatic cleavage assay 
(Figure 41C). The results showed that the efficiency was approximately 31% compared to 




Figure 41. Assessment of cleavage efficiency of CRISPR/Cas9-GFP. The CRISPR/Cas9-GFP 
was transfected into HEK293T cells (A, B). The efficiency of CRISPR/Cas9-GFP confirmed by 
cleavage assay was around 31% (C, D). Non-transfected HEK293T cells were used as negative 
control while the positive control was used from the commercial kit.   
 
Next, the CRISPR/Cas9-GFP plasmid was transfected into Vici-iPSCs. However, GFP 
fluorescence was weak and the efficiency of nucleofection in iPSCs was relative low, about 
10-15% (Figure 42A). Sorted GFP
+
 single cells were subsequently cultured and amplified. 
Altogether, 150 GFP
+
 colonies were obtained, from which genomic DNA was extracted. 
The PCR results showed the abnormal pattern of the EPG5 gene in 4 colonies (Figure 
42B), suggesting that NHEJ happened in the cells to repair the DNA double-stranded break 
caused by the CRISPR/Cas9 cutting. Furthermore, after restriction digestion of the PCR 
products by Hind III, it was inferred that EPG5 was targeted in two colonies. However, the 
DNA sequencing results revealed that the inserted Hind III in both clones was generated by 
NHEJ rather than homologous recombination (Figure 42C). NHEJ resulted in nucleotide 




Figure 42. Representative clones after the genomic editing. The efficiency of Vici-iPSCs 
nucleofected with CRISPR/Cas9-GFP was around 13.5% (A). Different genomic DNA PCR 
products were observed in different clones (B). The sequence of the PCR product that could be 
cut by Hind III contained 20bp nucleotide deletion in the genomic DNA (C). 
 
Taken together, the data showed that the CRISPR/Cas9-GFP system functioned in 
Vici-iPSCs to introduce DNA double-stranded break with a low efficiency. Among 150 
GFP
+





In this study, the patient-specific iPSC platform was used to investigate the Vici 
syndrome associated cardiomyopathy and the underlying molecular mechanism in vitro. 
First, Vici-iPSCs were generated from a patient with Vici syndrome with a homozygous 
intronic mutation in EPG5 gene (c.4952+1G>A). Ctr-iPSCs used in this study were 
generated from healthy controls as previously published (Dudek et al., 2013; Liu et al., 
2016; Streckfuss-Bomeke et al., 2013). Positive alkaline phosphatase staining, high 
expression of pluripotent-related markers and spontaneous differentiation into derivatives 
of three germ layers in vitro and in vivo demonstrated the pluripotency of the three 
generated and analyzed Vici-iPSC lines. Furthermore, the Ctr- and Vici-iPSCs were 
differentiated into functional cardiomyocytes, shown as spontaneous contraction with 
expression of cardiac-related markers. Structural analysis of cardiomyocytes revealed that 
Vici-iPSC-CMs displayed the normal sarcomere length but exhibited a multidirectional 
sarcomere organization. Although the cell volume of Vici-iPSC-CMs was comparable 
with that of Ctr-iPSC-CMs, the cell surface area of Vici-iPSC-CMs was significantly 
larger compared with Ctr-iPSC-CMs. Analysis of force of contraction in EHM showed a 
similar concentration-dependent positive inotropic response to increasing extracellular 
calcium concentrations in Vici-EHMs and Ctr-EHMs. In Vici-iPSC-CMs, strong baseline 
accumulation of LC3I and LC3II as well as increased ratio of conversion between LC3II 
and LC3I was visible that was largely unresponsive to the treatment with rapamycin and 
bafilomycin. Autophagosome accumulation (as indicated by LC3II-positive puncta) and 
abnormal localization of lysosomes (as indicated by LAMP1-positive puncta) in untreated 
Vici-iPSC-CMs as well as the fusion blockade of autophagosomes with lysosomes after the 
rapamycin and bafilomycin treatment further illustrated the autophagic disorder in 
Vici-iPSC-CMs. Investigation of the main autophagy regulation pathway 
(PI3K/AKT/mTOR) revealed that phosphorylation of AKT (T308 and S473), FOXO3  
(T32)/FOXO1 (T24) and mTOR (S2428) was downregulated in Vici-iPSC-CMs, 
indicating that the PI3K/AKT/mTOR pathway is involved in the autophagy defect in 
Vici-iPSC-CMs. Furthermore, in this study, the CRISPR/Cas9 technique was used to 
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rectify the mutation in EPG5 for rescuing the phenotypes observed in Vici-iPSC-CMs. 
Although no isogenic Vici-iPSCs with the corrected EPG5 gene were generated, the data 
indicate that the CRISPR/Cas9 technique functions in Vici-iPSCs. 
4.1 The generated Vici-iPSCs are pluripotent 
In this project, iPSCs were generated from the patient with Vici syndrome with the EPG5 
mutation (c.4952+1G>A) and three iPSC lines were proved to be pluripotent. However, 
the iPSC generation from the patient with this rare disease was complex. Fibroblasts 
derived from the patient with Vici syndrome proliferated slowly in vitro and showed a 
planar morphology and significantly larger size compared to normal healthy fibroblasts 
(data not shown). Different methods including Sendai virus and STEMCCA lentivirus 
transduction as well as plasmid transfection to deliver the transcription factors OCT4, 
SOX2, KLF4 and c-MYC were applied to generate Vici-iPSCs, however, Vici-iPSCs 
could be generated only through the STEMCCA lentivirus transduction. The difficulty of 
transducing of Vici fibroblasts perhaps is due to the slow proliferation of fibroblasts, 
which may result from the autophagy defect (Cullup et al. 2013). Additionally, autophagy 
is required for reprogramming of somatic cells into iPSCs. The delicate balance of 
mTORC1 inhibition and autophagy induction coordinated by OCT4, SOX2, KLF4 and 
c-MYC in the early phase of reprogramming determines the reprogramming efficiency 
(Wang et al., 2015; Wang et al., 2013; Wu et al., 2015).  
 
Sendai virus and plasmid nucleofection are advantageous to generate safe iPSCs for 
further understanding disease phenotype and the underlying molecular mechanism 
because of carrying no risk of altering host genome (Fusaki et al., 2009; Si-Tayeb et al., 
2010). However, in this study, Vici syndrome-specific fibroblasts deteriorated 4-6 days 
after Sendai virus transduction. Previous studies showed that apoptotic cell death could 
be induced by blocking the autophagic flux in different cell types and autophagy plays 
functional roles in defence in infections (see review by (Marino et al., 2014)). In addition, 
virus infect could inhibit the autophagic flux (Granato et al. 2014, Metz et al. 2015). The 
death observed in Vici fibroblasts after Sendai virus infection might be due to the cell 
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death induced by the block of the autophagic flux in Vici fibroblasts resulted from the the 
EPG5 mutation (Cullup et al. 2013), which might be further enhanced by the Sendai virus 
infection. Compared to the Sendai virus system, the STEMCCA lentivirus transduction is 
advantageous, (1) because it contains the four necessary transcription factors in a single 
polycistronic vector so that less virus particles are needed for the successful 
reprogramming; and (2) because the STEMCCA lentivirus can infect both diving and 
non-dividing cells, especially, when taking the slow proliferation rate of Vici fibroblasts 
into account. But STEMCCA lentivirus possesses the risks to disrupt the genomic 
information and leads to insertional mutagenesis because of the random integration into 
host genome (Somers et al., 2010).  
 
Proof of pluripotency showed that all analyzed iPSC lines expressed high levels of 
pluripotent-related markers such as OCT4, SOX2, KLF4, LIN28, NANOG and SSEA4. 
In vitro differentiation of Vici-iPSCs showed expression of specific markers for different 
cell types derived from all three embryonic germ layers, illustrating that they are 
pluripotent. Teratomas derived from Vici-iPSCs were small and histological analysis 
showed that these teratomas contained intestinal tissue (endoderm), muscle-like cells 
(mesoderm) and neural-like cells (ectoderm). The formation of teratoma is a gold 
standard to prove the pluripotency of iPSCs (Przyborski, 2005). However, the reason for 
the small teratoma formation is unclear; perhaps it results from cell apoptosis after 
injection or autophagy defect (Nelakanti et al., 2015; Zhang et al., 2008). 
 
In this study, the remodeling of epigenetic markers during reprogramming of somatic 
cells into pluripotent state, such as the demethylation on the promoters of key 
endogenous pluripotent markers OCT4 and NANOG (Marson et al., 2008), is not 
determined in the Vici-iPSCs and needs to be further investigated.  
 
Genomic stability during long-term culture of iPSCs is important for analyzing the 
relationship between the disease phenotype and gene mutation. Previous study showed 
that genomic instability occurs in all cell types in long-term culture and karyotypic 
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aberrations in hiPSC cultures are similar to those of hESCs (Martins-Taylor and Xu, 
2012). Recurrent aneuploidies were detected during the prolonged culture of hESCs with 
G-banded karyotyping, including trisomy 12, trisomy X (female hESC lines) and 
amplification of chromosome 17 (Draper et al., 2004). To ensure genetic stability in the 
cell lines used in this study, they were used at passages earlier than 35. The majority 
(95%) of Vici-iPSCs analyzed with G-banded karyotyping at 30 passages exhibited a 
normal diploid karyotype with 46 chromosomes (data not shown). But the traditional 
G-banded analysis has its limitations; its capability is limited to larger chromosomal 
aberration detection and failure to detect amplification and deletion of small regions. 
New technologies including fluorescent in situ hybridization, array-based comparative 
genomic hybridization and single-nucleotide polymorphism based microarray can be 
applied to detect karyotypic abnormalities and copy number variations.  
 
The mutation (c.5921+1G>A) in the EPG5 gene was verified by sequencing in the 
analyzed Vici-iPSCs and the missing of exon 28 in EPG5 was confirmed by RT-PCR on 
mRNA level. However, in order to figure out if EPG5 deficit is the only reason to cause 
the disease phenotype, the genomic DNA should be sequenced because the STEMCCA 
lentivirus-based reprogramming used in this study was possible to generate unknown 
mutations in the host genome. 
 
Taken together, these generated Vici-iPSCs have similar characteristics as hESCs 
regarding to the morphology, expression of pluripotent-related genes and capability of 
differentiation. With the same genetic background of the patient with Vici syndrome, 
Vici-iPSCs carrying the EPG5 mutation are suitable for modeling Vici syndrome and 
uncovering the molecular mechanism of the disease. 
4.2 Cardiomyocytes derived from hiPSCs are embryonic-like cells 
In this study, cardiomyocytes at late stages (60-90 days old) were used for studying the 
disease phenotype of Vici syndrome in vitro. HiPSC-CMs provide significant advances 
for studying the cardiac disease and treatment due to their unlimited production from 
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patient-specific iPSCs. Cardiomyogenic differentiation protocols via modulating of the 
Wnt signaling pathway by CHIR99021 and IWP2 yield cardiomyocytes with a high 
purity (over 90%). Majority (more than 80%) of the cardiomyocytes are ventricular-like 
cells. However, hiPSC-CMs possess molecular signature and phenotypes that resemble 
embryonic cardiomyocytes rather than adult cardiomyocytes (Robertson et al., 2013). 
First, most of hiPSC-CMs appeared as a small and rounded morphology with 
mono-nuclei while adult CMs are large and cylindrical (rod-like morphology) with 
double or multiple nuclei. In addition, the extensive T-tubule network found in mature 
adult cardiomyocytes is absent in hiPSC-CMs. These networks are responsible for the 
excitation-contraction coupling involving precise communication between L-type 
calcium channel located mainly on the T-tubules and calcium release channels/ryanodine 
receptor channels on the sarcoplasmic reticulum in adult CMs. However, calcium in 
hiPSC-CMs primarily enters the cell through sarcolemma and results in a slow 
excitation-contraction coupling (Lieu et al., 2009). For energy supply, the hiPSC-CMs 
depend on glycolysis for the production of ATP and could metabolize lactate and glucose 
whereas adult CMs mainly utilize oxidative metabolism (Tohyama et al., 2013). 
 
To induce their maturation similar to adult cardiomyocytes, hiPSC-CMs were cultured for 
extended time (80-120 days post initial beating), resulting in maturation of their structure, 
contractile elements and electrophysiology to a more adult-like phenotype compared with 
early stage (20-40 days post initial beating) cell cultures (Lundy et al., 2013). The authors 
demonstrated that hiPSC-CMs at late stages showed high expression of cardiac structural 
genes, greater myofibril density and alignment, increased calcium release and reuptake 
rates without maximum amplitude changes, and better electrophysiology properties 
(hyperpolarized maximum diastolic potentials, increased action potential amplitude and 
faster upstroke velocities). However, although the long-term culture could enhance the 
maturation of hiPSC-CMs, the pool of differentiated cells still contains a heterogeneous 
population of cells that recapitulate some features of embryonic cardiomyocytes. 
Modifying the cardiomyocyte culture condition would enhance their maturation in vitro. 
For instance, Tri-iodo-L-thyronine (T3), a growth hormone that is expressed in neonatal 
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cardiomyocytes and enhances normal cardiac maturation in vivo, could enhance the 
maturation of hiPSC-CMs (Yang et al., 2014). It remains unclear what is the best 
approach to enhance the maturity of hiPSC-CMs. Despite current immature states of 
hiPSC-CMs, these cells still possess great potential for modeling phenotypes of cardiac 
diseases, especially for the diseases like Vici syndrome, which is an early-onset disease.  
4.3 Vici-iPSC-CMs recapitulate the cardiac phenotype of the patient with Vici 
syndrome 
4.3.1 Vici-iPSC-CMs show disorganized sarcomere structures  
More than 80% of patients with Vici syndrome possess a hypertrophic or dilated 
cardiomyopathy especially in the left ventricle ((Byrne et al. 2016a). In this study, when 
attached to the cell culture dish, Vici-iPSC-CMs displayed larger cell surface area than 
Ctr-iPSC-CMs, but without showing an increased cell volume when detached. Similar 
phenomenon was observed together with an increased viscoelasticity in cardiac 
fibroblasts after the downregulation of RhoA (Jatho A et al. 2015). However, it is largely 
unclear why Vici-iPSC-CMs show this phenomenon, and did not show an increase in cell 
volume as expected. One explanation can be that the cells are still too young to 
demonstrate the hypertrophic phenotype. Previous study showed that the ratio of surface 
area/volume of cardiomyocytes undergoes significant developmental changes (Satoh H et 
al. 1996). Furthermore, many complicated and diverse signaling pathways regulate cell 
sizes in different cell types. Dividing and non-dividing adult cell maintains a constant cell 
size in a homeostatic state for balancing the synthesis and degradation of macromolecules 
(Koivusalo et al., 2009). The PI3K/AKT/mTORC1 pathway is mainly involved in the 
regulation of autophagy and studies have demonstrated that this pathway regulates cell 
proliferation and is also a key determinant of cell size, with the artificial activation of this 
pathway during development resulting in larger animals that could result from 
hypertrophic cells (Edgar, 2006; Laplante and Sabatini, 2012; Tumaneng et al., 2012). 
Over-activation of mTOR may cause accumulation of defective cellular structures and 
organelles, which may result in age-related cardiac hypertrophy (Lloyd, 2013; Loffredo et 
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al., 2013).  
 
Hypertrophic cardiomyopathy is normally characterized by increased cell size, 
heightened organization of sarcomere and enhanced protein synthesis at the cellular level 
(Frey et al., 2004). Sarcomeric analysis showed that Vici-iPSC-CMs exhibited normal 
sarcomere length but higher inhomogeneity of sarcomere length. This, however, did not 
result in a significant functional consequence (no significant difference in force of 
contraction) from the analysis of EHMs. Evidence of such disorganization of sarcomere 
arrangements was demonstrated in mice with the tamoxifen-inducible cardiac-specific 
knockout of autophagy related atg5, in which cardiomyocytes showed disorganized 
sarcomere and contractile dysfunction (Nakai et al., 2007). Thus, we conclude that the 
abnormal sarcomere distribution in Vici-iPSC-CMs is attributed to the autophagy defect, 
which might lead to hypertrophic/dilated cardiomyopathy. To further confirm the 
phenotype, future study should be performed in even older Vici-iPSC-CMs or after the 
stress application. Additionally, the molecular level changes accompanied by activation 
of fetal genes such as atrial natriuretic factor and beta-myosin heavy chain should be 
clarified.    
4.3.2 The autophagic flux is blocked in Vici-iPSC-CMs 
Through analyzing the expression and localization of LC3, P62, NBR1 and LAMP1, we 
found the block of autophagic flux in Vici-iPSC-CMs, as indicated by the accumulation 
of the LC3II-positive autophagosomes and by the impaired fusion of autophagosomes 
with lysosomes.  
 
Protein quality and quantity control rely on the proteasomes and lysosomes that are 
responsible for protein degradation in UPS and autophagy. However, it is still unknown 
how the different protein lytic systems including lysosomes, proteasomes and other 
protease are orchestrated to maintain protein stasis in various cell types under the 
physiological or pathological conditions (Wang and Robbins, 2014). Mostly, the naive 
and misfolded proteins are ubiquitinated with a cascade of enzymatic reactions that are 
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catalyzed sequentially by E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating 
enzyme), and E3 (ubiquitin ligase). The aggregated proteins are degraded with the 
autophagy pathway while the organelles such as mitochondria and ribosomes tend to 
choose the selective autophagy through P62 and NBR1. But it has not been studied in this 
study whether Vici-iPSC-CMs causes the compensatory reaction from UPS and other 
proteolysis machinery.  
 
The accumulation of autophagosomes and abnormal autolysosome formation in 
Vici-iPSC-CMs were also observed in Vici fibroblasts and skeletal muscle biopsy (Cullup 
et al. 2013) and lysosomal disorder disease (LSD), such as X-linked recessive Danon 
disease resulting from the mutation of LAMP2 (Nishino et al., 2000). Abnormal 
autophagosome accumulation was also visible in other LSD diseases such as Pompe 
disease, multiple sulfatase deficiency, mucopoly-saccharidosis type IIIA, mucolipidosis 
type IV and Gaucher disease (Curcio-Morelli et al., 2010; Fraldi et al., 2010; Sun et al., 
2010; Tessitore et al., 2009; Venugopal et al., 2009; Vergarajauregui et al., 2008). 
Furthermore, the observation of the perinuclear localization of lysosomes in 
Vici-iPSC-CMs is also in line with those observed in LSD, in which the autophagosome 
accumulation is caused by a defect of lysosome biogenesis. These similar autophagy 
abnormalities in both LSD and Vici syndrome suggest that these disorders may intricately 
link to the same or related molecular pathways, which are perhaps associated with defects 
concerning intracellular trafficking or lysosome transport. Further investigation of EPG5 
function such as its interaction proteins could be beneficial to uncover the molecular 
mechanism for the autophagosome accumulation and lysosome biogenesis defect in these 
diseases.  
 
The disrupted autophagy could result in the accumulation of dysfunctional mitochondria 
that generate reactive oxygen species (ROS), which play a major role in the development 
of cardiovascular diseases (Linton et al., 2015). In this study, similar localization of 
COXIV-positive mitochondrial membranes between Ctr-iPSC-CMs and Vici-iPSC-CMs 
was observed. In order to assess if the autophagy defect causes mitochondrial dysfunction, 
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better markers such as oxygen consumption rate, extracellular acidification rate, ATP 
production and respiratory capacity of mitochondria could serve as better indicators. 
 
Collectively, we found in this study the accumulation of autophagosomes, the fusion 
impairment of autophagosomes with lysosomes as well as the abnormal perinuclear 
localization of lysosomes in Vici-iPSC-CMs.      
4.3.3 The PI3K/AKT/mTORC1 pathway is involved in the autophagy defect in 
Vici-iPSC-CMs 
In this study, decreased phosphorylation of AKT at two different activating sites T308 
and S473 was found in Vici-iPSC-CMs. The major regulation pathway of autophagy is 
PI3K/AKT/mTORC1. Full activation of AKT results in phosphorylation of other proteins 
and mediates numerous cellular functions including cell growth, survival and apoptosis, 
protein synthesis, and cell metabolism. Aberrant regulation of phosphorylation of AKT is 
implicated in a number of human diseases including cancer, diabetes and cardiovascular 
diseases. For instance, the phosphorylation of AKT in cancer and human tumors is 
abnormally increased (Testa and Tsichlis, 2005). However, the relationship between the 
autophagy defect caused by EPG5 truncation and the reduced AKT phosphorylation in 
Vici-iPSC-CMs is still unknown. AKT activity is regulated by a plethora of proteins to 
keep in balance (Figure 43). PDK1 at the membrane is responsible for phosphorylation 
of AKT at T308 leading to partial activation of AKT (Andjelkovic et al., 1996). Further 
phosphorylation of AKT at S473 by mTORC2 stimulates its full enzymatic activity 
(Guertin et al., 2006). Members of the PI3K-related kinase (PIKK) family such as 
DNA-dependent protein kinase (DNA-PK) can also phosphorylate AKT at S473 (Feng et 
al., 2004). To avoid irregular phosphorylation of AKT, protein phosphatase 2A (PP2A), 
the PH-domain leucine-rich-repeat-containing protein phosphatases (PHLPP1/2) and the 
tumor suppressor PTEN dephosphorylate AKT to inhibit AKT activity (Andjelkovic et al., 
1996; Brognard et al., 2007; Stambolic et al., 1998). Investigation of upstream regulatory 
proteins of AKT would be useful for studying the molecular mechanism of Vici syndrome 




Figure 43. The schematic representation of partial AKT and mTORC1 cellular pathways. 
Both AKT and mTORC1 pathways are controlled by multiple upstream proteins, and regulate 
many downstream proteins to monitor the biological processes.  
 
The downstream proteins of AKT, FOXO3 T32 and FOXO1 T24, showed reduced 
phosphorylation in Vici-iPSC-CMs, which thus may promote the function of active FoxO 
to activate gene expression that regulates cell death, cell cycle arrest and ROS production 
(Brunet et al., 1999; Gopinath et al., 2014; Myatt and Lam, 2007; Skurk et al., 2004). 
Expression of active FOXO3 can also directly induce autophagy and UPS in muscle cells 
(Mannis, 1987; Sippel, 1972) and induce expression of a number of autophagy-related 
genes including LC3 (Ravikumar et al. 2010). These data are in line with the upregulation 
of LC3 expression in Vici-iPSC-CMs. AKT also phosphorylates and inactivates the 
TSC1/TSC2 complex that negatively regulates mTORC1 to inhibit autophagy (Inoki et 
al., 2002). In this study, the decreased phosphorylation of mTOR at S2448 (activating site) 
was detected in Vici-iPSC-CMs, suggesting that the autophagy might be enhanced in 
Vici-iPSC-CMS. In addition, the reduced phosphorylation of mTOR perhaps leads to the 
reduced phosphorylation of AKT S473 that is directly activated by mTORC2.  
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The activity of mTORC1 is controlled by its upstream protein TSC1/2 complex that is 
regulated by multiple upstream signals (Figure 43). The effector kinases of Ras pathway 
Erk1/2 (extracellular-signal-regulated kinase1/2) and RSK1 (ribosomal S6 kinase) 
directly phosphorylate and inactivate the TSC1/2 complex and thus activate mTORC1 
(Ma et al., 2005; Manning et al., 2002). The pro-inflammatory cytokines such as tumor 
necrosis factor- (TNF) activate mTORC1 similar to AKT, Erk1/2, RSK1 and IkB 
kinase (IKK) by phosphorylating TSC1/2 to inhibit their function (Inoki et al., 2002; 
Lee et al., 2007). The Wnt pathway also activates mTORC1 by inhibiting GSK3to 
phosphorylate TSC2 and promote TSC1/2 activity (Inoki et al., 2006). The preliminary 
analysis of the expression of total and phosphorylated GSK3 showed no significant 
differences in Vici-iPSC-CMs compared to Ctr-iPSC-CMs, suggesting that the Wnt 
signaling pathway does not influence the defective autophagy in Vici-iPSC-CMs. 
Furthermore, in hypoxia, energy deficit and DNA damage condition, TSC2 is 
phosphorylated to activate TSC1/2 through a cascade of proteins including DNA damage 
response 1 (REDD1), AMPK and P53, respectively, which negatively regulate mTORC1 
(Brugarolas et al., 2004; Budanov and Karin, 2008; Feng et al., 2005; O'Brien and 
Elixson, 1990; Reiling and Hafen, 2004; Stambolic et al., 2001). Taken together, 
autophagy is regulated by mTORC1 but mTORC1 has a diverse function in protein 
synthesis, lipid synthesis, lysosome biogenesis, and energy metabolism (Figure 43). 
 
In this study, rapamycin and bafilomycin are used for the induction and blockade of 
autophagy, respectively. Rapamycin treatment was supposed to inhibit mTORC1 
efficiently, which theoretically suppresses the phosphorylation of P70S6K. But the 
phosphorylation of P70S6K was not changed after rapamycin and combined rapamycin 
and bafilomycin treatment in both Ctr- and Vici-iPSC-CMs. In addition, Expression and 
phosphorylation of P70S6K in untreated Vici-iPSC-CMs was similar to Ctr-iPSC-CMs. 
The unchanged phosphorylation of P70S6K in Vici-iPSC-CMs suggests that P70S6K 
might also be regulated by other mTOR-independent signaling.  
 
Besides the main PI3K/AKT/mTOR pathway to regulate autophagy, other 
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mTORC1-independent pathways are also involved. For example, second messenger IP3 
(inositol 1,4,5-trisphosphate), cAMP-Epac-PLC-ε-IP3 and Ca
2+
-calpain-Gs pathways 
negatively regulate autophagy (Sarkar et al., 2005; Sarkar et al., 2009; Williams et al., 
2008). In the future, these pathways need to be investigated in Vici-iPSC-CMs. 
4.4 No isogenic control of Vici-iPSCs has been generated 
In this study, the CRISPR/Cas9 technology was applied to correct the EPG5 mutation. 
However, none of the 150 selected colonies possessed the “corrected” EPG5 gene. To 
rectify the mutation, the methods could be further modified in the future as following: (1) 
the oligonucleotides could be redesigned with appropriate length of homologous arms or 
the donor construct instead of single-stranded oligonucleotides should be designed; (2) 
the culture medium should be supplemented with a compound such as L755507 and 
Brefeldin A that could improve the efficiency of homology-directed repair (Yu et al., 
2015); (3) the double-nicking approach should be applied to improve Cas9 targeting 
recognition fidelity through “sticky ends” generated by DNA single-stranded breaks (Ran 
et al., 2013), which are repaired via the high-fidelity base excision repair pathway to 
increase the specificity of NHEJ as well as homologous recombination. Recently, 
Natronobacterium gregoryi Argonaute as a DNA-guided endonuclease was discovered 
suitable for genome editing in human cells (Gao et al., 2016), which might be applied in 
the future to correct the EPG5 mutation.  
 
Specificity of CRISPR/Cas9/sgRNA is affected by several factors, including the number, 
position and distribution of the mismatches in speculated off-target sites, enzymatic 
concentration of Cas9 as well as duration of Cas9 expression (Fu et al., 2013; Hsu et al., 
2013; Mali et al., 2013a; Pattanayak et al., 2013). Duration of Cas9 expression after 
transduction to cells remains to be carefully investigated. In addition, whether the 
predicted off-target sites were recognized and cut by Cas9, it should be investigated 
further with whole genome sequencing or other unbiased ways of labeling DNA double 




In this study, the plasmid of CRISPR/Cas9 was linked with GFP to conveniently sort 
transfected iPSCs. The plasmids were easily transfected into HEK293T with high 
efficiency (50%-70%, with strong green fluorescence) as compared to Vici-iPSCs 
(10%-15%, with weak green fluorescence). Low green fluorescence signals were 
observed in Vici-iPSCs, which could be attributed to the silencing of CMV promoter of 
GFP. Therefore, to allow better sorting of GFP-positive Vici-iPSCs, control of GFP 
expression under a strong promoter such as EF-1alpha could be employed.  
4.5 Possible treatment of Vici syndrome 
Vici syndrome is the first multisystem disorder with a primary autophagy defect reported 
until now. Autophagy as a secondary phenotype has been implicated in many diseases 
such as cancer, neurodegeneration diseases, infectious diseases, myopathies and 
metabolic diseases. Therefore, autophagy modulation could be a potential therapeutic 
target for a wide range of diseases. Briefly, the diseases might be treated by upregulation 
or inhibition of autophagy due to its protective or destructive role in the progression of 
the disease. For instance, defects in autophagosome formation may be susceptible to 
enhance the autophagosome biogenesis; autophagy should be induced in infectious 
diseases to degrade the intracellular bacterial infections; autophagy should be inhibited in 
cancer cells as a tumor suppressor to prevent tumorgenesis. 
 
The known pharmacological methods of modifying autophagy receive currently 
considerable attention (Rubinsztein et al., 2012; Yang et al., 2011). The drugs for 
induction of autophagy include mTROC1 inhibitor rapamycin and its analogues such as 
CCI-779, RAD001 and AP23573; mTOR kinase inhibitors including Torin1 and PP242; 
or mTOR independent drugs clonidine, rilmenidine, carbamazepine, trehalose, and 
Tat-beclin1 etc. Autophagy inhibitors consist of lysosomotropic inhibitors such as 
chloroquine, hydroxychloroquine, bafilomycin A1, nocodazole, and Lys05, autophagic 
machinery inhibitors such as 3-methyladenine and its derivatives PIK3C3 inhibitors, 
ATG4B inhibitors and ATG7 inhibitors etc (Huang and Klionsky, 2007). However, many 
of these drugs are still not applicable for clinical use. Currently, cancer is the first disease 
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target for clinical trials that utilize the inhibition of autophagy in patients. Lysosomal 
inhibitor chloroquine and hydroxychloroquine that are applied to cure malaria are used in 
first round of Phase I/II clinical trials in cancer (Amaravadi et al., 2011; Yang et al., 2011). 
Phase I/II clinical trials showed promising results that hydroxychloroquine combined 
with chemotherapy and radiation therapy can stabilize aggressive cancers such as 
glioblastoma, melanoma, lymphoma and myeloma, renal and colon cancers. Indeed, to 
overcome the resistance to existing mTOR inhibitors, advanced mTOR inhibitor such as 
RapaLink-1 was explored recently and is prospective for treating the resistant tumors 
(Zhao et al., 2016).  
 
Inhibition or induction of autophagy would be useful for studying cancer and 
neurodegenerative diseases; however, this method will not work for treating the diseases 
with defective maturation of autophagosomes and autolysosomes, such as Vici syndrome 
and lysosomal disorder. Therefore, further characterization of the precise biological role 
of EPG5 and finding the downstream protein as well as drug screening for promoting the 
fusion of autophagosomes with lysosomes will provide potential targets to treat Vici 
syndrome.  
4.6 Conclusion and outlook 
In conclusion, the findings of this study suggest that patient-specific iPSCs could be used 
to understand the function of autophagy in cardiomyocytes. Vici-iPSCs were generated 
from the patient with Vici syndrome carrying the EPG5 mutation. Vici-iPSCs were 
pluripotent and could be differentiated into functional beating cardiomyocytes. 
Furthermore, Vici-iPSC-CMs possessed disorganized sarcomere structure, accumulated 
autophagosomes, perinuclear lysosomes, blocked autophagosome-lysosome fusion and 
downregulated AKT activity. The data demonstrate that hiPSC-CMs are suitable to model 
the early onset disease such as Vici syndrome even though they resemble immature 
cardiomyocytes. 
 
In the future, the EPG5 mutation may be rectified by genomic editing tools to rescue the 
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disease phenotype observed in Vici-iPSC-CMs. Besides the analysis of sarcomere 
structure, functional contractility and autophagy defect, it is not known whether 
autophagy defect causes abnormal cardiac electrophysiological features such as action 
potential, excitation-contraction coupling and functional defect of ion channels. It is 
important to discover the precise biological role of EPG5 in physiological or pathological 
conditions and to elucidate mechanism of the autophagy defect in inherited multisystem 
disorder. To discover the molecular mechanism of Vici syndrome, the physiological 
function of EPG5 such as interaction proteins, cellular trafficking pathway and lysosome 
biogenesis should be figured out. Vici-iPSCs with primary autophagy defect also provide 
a platform for discovering the important role of autophagy in various tissues such as 
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Appendix 1: Side project 1 
Patient-specific iPSCs modelling TTN mutation caused cardiomyopathy 
1 Introduction 
 
Titin (TTN) is a giant protein with molecular weight ~4000 kDa found in striated muscles. 
It is encoded by the TTN gene that consists of 364 exons. The structure of the TTN 
protein is composed of protein domains with highly repetitive sequences, which include 
immunoglobulin-like domains (IgG, n=152), fibronectin 3 (Fn3, n=132), regulator of 
chromosome condensation 1 (RCC1, n=17), Kelch (n=19), tetratricopeptide repeat (TPR, 
n=14), solenoid WD domains (n=15) and PEVK domains (proline, glutamate, valine and 
lysine, n=60). In addition, TTN protein contains a titin kinase (TK) domain (Chauveau et 
al., 2014). 
 
There are three main titin isoforms: N2A, N2B and N2BA, as well as three rare isoforms: 
NOVEX1, NOVEX2 and NOVEX3 (Bang et al., 2001; Furst et al., 1988; Hackman et al., 
2002; Linke and Hamdani, 2014; Miller et al., 2003; Vikhlyantsev and Podlubnaya, 2012). 
The TTN gene could theoretically generate over 1 million splice variants with a wide 
range of protein size. However, the number of TTN protein variants thus far 
demonstrated experimentally is lower than expected. NOVEX3 (~616 kDa) is the 
smallest isoform of TTN and expressed in all striated muscles; N2A (~3680 kDa) has 
been identified as the main TTN isoform in the skeletal muscle; in cardiomyocytes, there 
are two main cardiac isoforms N2B (~2960 kDa) and N2BA (~3780 kDa) and additional 
isoforms NOVEX1 (~2980 kDa) and NOVEX2 (~2980 kDa) (Bang et al., 2001; Freiburg 
et al., 2000).  
 
TTN is the only single molecular element spanning from the Z disk to the M line in the 
sarcomere, which is important for the sarcomere assembly, stabilization and muscle 
elasticity. This has been demonstrated in a variety of experiments, for example, zebrafish 
mutants of cardiac specific N2B demonstrated poor contractility from the first beat, 
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nascent myofibril formation and abnormal sarcomere structure (Xu et al., 2002). 
Specifically knocking-out only the N2B exon 49 in mice showed that N2B region is 
important for the elastic functions of the heart (Radke et al., 2007). Deletion of the TK 
domain from cardiac TTN in mice leads to the absence of homozygous offspring 
(Gotthardt et al., 2003). Additionally, next generation sequencing revealed that mutations 
in TTN (mostly heterozygous) were observed in dilated cardiomyopathy (DCM), 
hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and restrictive cardiomyopathy (RCM). Furthermore, due to the difficulty for 
acquiring human heart tissue and size of titin protein, little is known about the precise 
molecular and pathophysiological mechanisms related with different TTN mutations. 
Thus, induced pluripotent stem cells (iPSCs) provide a good platform to generate 
unlimited cardiomyocytes and might be suitable to study the cardiac phenotype and the 
underlying molecular mechanism of cardiomyopathy caused by TTN mutations. 
Cardiomyocytes derived from DCM patient-specific iPSCs with TTN mutations showed 
sarcomere insufficiency, impaired responses to mechanical and beta-adrenergic stress, 
and attenuated growth factor and cell signaling activation (Hinson et al., 2015).  
 
In this study, iPSCs were generated from a DCM patient with compound heterozygous 
TTN mutations (c.54710T>C and c.106359G>A) and differentiated into functional 
cardiomyocytes. The phenotype of patient-specific cardiomyocytes and the expression of 
TTN protein was investigated.  
 
2 Materials and methods 
 
2.1 TTN-iPSC generation  
Patient-specific iPSCs were reprogrammed from the fibroblasts, which were derived from 
a DCM patient with compound heterozygous mutations (c.54710 T>C and c.106359 G>A) 
in TTN. Fibroblasts at passage 8 were transduced with Sendai virus reprogramming kit 
(Thermo Fisher Scientific) at MOI 2.5-2.5-1.5. The independent single iPSC colonies 
were picked 30 days post transduction and extended to generate stable iPSC lines. Among 
the cell lines, isTTN1.1, isTTN1.3 and isTTN1.4 were characterized for the pluripotency 
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and were used for subsequent experiments and studies.  
 
2.2 Titin protein detection  
Low percentage gel (2%) consisting of 2.5 ml buffer (1.5 M Tris (pH 8.8) with 0.4% 
SDS), 2.95 ml H2O, 0.7 ml 30% acrylamide, 100 l APS, 5.75 l TEMED and 3.39 ml 
1.5% agar was used to detect the TTN protein. The gels were subjected to electrophoresis 
for 12-16 h at low voltage (~20 V) and further used in coomassie staining and Western 
blot. TTN protein was detected with primary antibodies against the titin domain M8 and 
Z1Z2 (antibodies were produced in Mathias Gautel’s lab).  
 
2.3 RT-PCR 
Total RNA was isolated using the SV total RNA isolation system (Promega) according to 
the manufacturer’s instructions. 200 ng complementary DNA (cDNA) was synthesized 
from isolated RNA with the reverse transcriptase (Invitrogen). The specific DNA 
products of titin were amplified with polymerase chain reaction (PCR). The primers for 
detecting two mutation sites (c.54710T>C and c.106359G>A) were: for: 
GCTGGACTCCTCCTTTGGAC, rev: ATATGGGATCTCCTGCAACCTCT; and for: 
CTGAACCAAAAGCTCCTGAACCAATTTC, rev: TCCTTGTGTAATGGCCTGTAGA 
ATGCAA, respectively. 
 
2.4 Immunofluorescence staining  
Cardiomyocytes fixed by 4% PFA were blocked with 1% BSA, and following 
permeabilization by 0.1% Triton X100 (Sigma), they were stained with primary 
antibodies against -ACTININ, cTNT, MYOMESIN (M line binding protein) and TTN. 
The antibodies for TTN include M8, M8A5, T12 and Z1Z2.   
Other methods used in this study were referred in the first chapter of this thesis.  
 
3 Results 
To investigate the cardiac phenotype at cellular level, patient-specific iPSCs (TTN-iPSCs) 
were successfully generated through overexpression of the transcription factors OCT4, 
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SOX2, KLF4 and c-MYC using the Sendai virus system. After cellular reprogramming, 
compound heterozygous mutations (c.54710T>C and c.106359G>A) in the TTN gene 
were verified in TTN-iPSCs (Figure 1D). Furthermore, analysis of pluripotency showed 
that these TTN-iPSCs were pluripotent, including positive alkaline phosphatase staining, 
expression of pluripotent-related markers OCT4, SOX2, NANOG, LIN28, SSEA4 and 
TRA1-60, normal karyotype (23+XY), capacity of differentiation into derivatives of three 
germ layers in vitro and in vivo (Figure 1A-C, E, F). 
 
To study the effect of TTN mutations on sarcomeric structure, these generated pluripotent 
TTN-iPSCs were directly differentiated into beating cardiomyocytes in vitro. 90% pure 
cardiomyocytes were obtained using our cardiac differentiation protocol. Cardiomyocytes 
derived from health control iPSCs (Ctr-iPSC-CMs) and TTN-iPSCs (TTN-iPSC-CMs) 
highly expressed cardiac-related markers such as TNNT2, MYL2, MYH7, NKX2.5 on gene 
transcription level demonstrated by the RT-PCR analysis and -ACTININ and cTNT on 
protein level demonstrated by immunofluorescence staining (Figure 2A-C).  
 
Next, to identify the cardiac phenotype caused by the TTN mutation, Ctr- and 
TTN-iPSC-CMs were immunostained with primary antibodies against the M line (M8 
and M8A5) and the Z disk (T12 and Z1Z2) of TTN (Figure 3A and C). M8A5 was 
specifically designed at the mutation site of TTN protein (c.106359 G>A, Trp to stop 
codon). The data demonstrated that TTN protein was not detectable in TTN-iPSC-CMs 
using the M8A5 antibody in contrast to the regular distribution of TTN with striated 
sarcomere structures in Ctr-iPSC-CMs (Figure 3C). Additionally, the primary antibody 
targeting the M line of TTN protein (M8) was also unable to detect clearly the TTN 
protein in TTN-iPSC-CMs (Figure 3A). Sarcomeric structures of TTN protein were only 
observed when the cells were incubated with specific antibody targeting the Z disk (T12 
and Z1Z2) in both TTN-iPSC-CMs and Ctr-iPSC-CMs (Figure 3A and C). The results 
from the Western blot further corroborated the immunofluorescence staining data, 
demonstrating that TTN protein was not detectable with the M8 antibody, but visible with 
Z1Z2 in TTN-iPSC-CMs. Three isoforms were detected by the Western blot: the very 
Appendix 1 
 127 
long embryonic/fetal N2BA isoform, the adult N2B isoform and the truncated NOVEX3 
isoform (Figure 3B and D).  
 
Mutation in the TTN gene is heterozygous, but the proteins were not detectable with the 
antibody specific for the M line of TTN. Hence, we hypothesize that the other mutation at 
c.54710 T>C might lead to an additional truncated protein, which is degraded through 
autophagy or ubiquitin proteasome system (UPS) processing. In order to determine and 
detect the other truncated protein, cardiomyocytes were treated with autophagy inhibitor 
bafilomycin (100 nM, 24 h) and UPS inhibitor IMG132 (50 M, 24 h). The results of 
immunofluorescence staining showed that TTN protein were still not detectable using the 
M8 antibody (Figure 4A and B) whereas other M line binding protein such as 
MYOMESIN was normally expressed in TTN-iPSC-CMs (Figure 4A). The degraded 
proteins were visible after the bafilomycin treatment on Western blot using the antibody 




Figure 1: Proof of pluripotency in TTN-iPSCs reprogrammed from TTN fibroblasts. (A) 
Representative TTN-iPSCs were alkaline phosphatase positive and expressed pluripotency 
markers OCT4, SOX2, NANOG, LIN28, SSEA4 and TRA-1-60. (B) All three TTN-iPSC lines 
showed high expression of pluripotent-related genes including FOXD3, GDF3, LIN28 and SOX2. 
hESCs: human embryonic stem cells; FB, fibroblasts isolated from the TTN patient; isTTN1.1, 
isTTN1.3 and isTTN1.4, three iPSC lines derived from the TTN patient. (C) Karyotype analysis 
showed the normal karyotypes of TTN-iPSCs at passage 40. (D) Compound heterozygous TTN 
mutations c.54710T>C and c.106359G>A were verified in derived iPSCs. (E) TTN-iPSCs 
spontaneously differentiated into cells of three different embryonic germ layers in vitro. The 
endoderm representative marker is alpha fetoprotein (AFP); the mesoderm representative marker 
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is smooth muscle actin (SMA) and ectoderm specific marker β-III-TUBULIN. The nuclei were 
stained with DAPI. (F) Histological staining of teratoma from TTN-iPSCs showed in vivo 
generation of derivatives of three embryonic germ layers including intestinal (endoderm), 






Figure 2. Cardiac differentiation of Ctr- and TTN-iPSCs. (A) Both Ctr- and TTN-iPSCs were 
differentiated into functional cardiomyocytes with high efficiency. (B) Ctr- and TTN-iPSC-CMs 
expressed the cardiac-related genes including TNNT2, MYH7, MYL2 and NKX2.5. (C) Ctr- and 





Figure 3. The M line of TTN was not visible in TTN-iPSC-CMs. (A) TTN-iPSCs-CMs showed 
abnormal expression of the M line of TTN protein using the M8 antibody. (B) TTN protein 
cannot be detected through Western blot analysis with primary antibody against M8 in 
TTN-iPSC-CMs. (C) The M line of TTN protein was not visible with specific antibody (M8A5) 
against the mutation site (c.106359G>A) in TTN-iPSCs-CMs. (D) Two fetal cardiac TTN 
isoforms N2B and N2BA as well as NOVEX3 were detected using the antibody Z1Z2 in 




Figure 4: Detection of TTN protein after bafilomycin and IMG132 treatment. (A, B) TTN 
protein were not be detected as sarcomeric structures using the M8 antibody in TTN-iPSC-CMs 
even after blocking the protein degradation pathway by bafilomycin (BafA1) and IMG132, 
respectively. The sarcomere structure was stained with the antibody against the Z disk of TTN 
(T12) and MYOMESIN. (C, D) Western blot analysis showed the degraded protein is visible after 




Next generation sequencing technologies revealed that TTN mutations were associated 
with cardiomyopathy. However, the underlying molecular mechanisms have not been 
clearly demonstrated. The current molecular study of TTN mutations and cardiomyopathy 
is limited due to the technical difficulty for cloning the full-length TTN gene, purification 
of this giant protein and obtaining native heart muscle. The mutation sites in the TTN 
gene were diverse and located in the Z disk, I band, A band and M line of the sarcomere. 
The TTN mutation investigated in this study is compound heterozygous, with a missense 
mutation (c.54710T>C, Leu>Pro) in the A band and a truncate mutation (c.106359G>A, 
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Trp to stop codon) in the M line. TTN protein plays a critical role at the M line to 
maintain structural integrity of sarcomere and myofibrillar signaling. The conditional 
knockout of TK domain in the M line in mice showed that homozygous deletion of the 
domain led to embryonic lethality whereas heterozygous deletion resulted in sarcomere 
structure disassembly (Gotthardt et al., 2003; Peng et al., 2005; Weinert et al., 2006). In 
this study, the mutation c.106359G>A (Trp to stop codon) in TTN leads to a truncated 
TTN protein at the M line, which is not detectable using the M line-specific antibodies 
(M8 and M8A5) as expected. However, as the mutation c.106359G>A (Trp to stop codon) 
is heterozygous, we do expect to detect TTN protein using the M line-specific antibodies 
in TTN-iPSC-CMs. Surprisingly, TTN protein was completely not detectable with 
specific antibodies M8 and M8A5 in TTN-iPSC-CMs. These data suggest that the other 
mutation at c.54710T>C in the other allele of TTN might lead to TTN protein instability 
and degradation. The unstable or truncated proteins might be degraded through 
autophagy or ubiquitin proteasome system (UPS) processing. Two fetal isoforms of TTN 
(N2B and N2BA) were detected with the antibody Z1Z2, but Western blot was unable to 
distinguish the truncated TTN from the normal TTN, due to the resulting similar protein 
size. In this study, a slightly enhanced degradation of TTN was observed only after 
blocking protein degradation pathways. Further studies need to investigate how the 
mutation c.54710T>C affects the TTN protein stability and degradation. Taken together, 
this study demonstrated that TTN-iPSCs could be used to elucidate the physiological role 
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X-linked myotubular myopathy (XLMTM) is an inherited neuromuscular disorder, which 
predominantly affects females and is characterized by muscle weakness present at birth, 
hypotonia, feeding difficulties and inability to maintain spontaneous respiration 
(Wallgren-Pettersson and Thomas, 1994). XLMTM is caused by mutations in the MTM1 
gene (in Xq28), encoding the myotubularin protein which functions as a phosphatase 
acting specifically on phosphatidylinositol 3-phosphate (PI(3)P) and phosphatidylinositol 
3,5-bisphosphate (PI(3,5)P2). Phosphoinositides (PIs) play an important role in lipid 
metabolisms, cell signaling and membrane trafficking. PI(3)P and PI(3,5)P2 directly 
participate in the endosomal-lysosome pathway (Heckmatt et al., 1985; Robinson and 
Dixon, 2006). Recently, defective PI conversion at endosomes was shown in the 
fibroblasts derived from XLMTM patients (Ketel et al., 2016). However, the studies on 
disease phenotype of skeletal muscle and the underlying molecular mechanisms in 
XLMTM patients were impeded due to the limited availability of the muscle biopsy. 
Human iPSCs are self-renewal and can differentiate in vitro into skeletal muscle cells, 
potentially providing unlimited supply of these tissues. Generating patient-specific 
skeletal muscle cells to model XLMTM in vitro provide new insights into our 
understanding of key signaling pathways and disease mechanisms involved in XLMTM.  
 
Current studies of myogenic differentiations from iPSCs rely on cell sorting or ectopic 
expression of myogenic regulators or small molecules. In a previously published study, 
hESCs were first co-cultured with stromal cells OP9 to induce mesenchymal precursor, 
which were sorted with CD73 and further co-cultured with C2C12 to lead the formation 
of myotubes (Barberi et al., 2005). Furthermore, the myogenic differentiation of hESCs 
and iPSCs was induced by formation of embryoid bodies (Awaya et al., 2012; Zheng et 
al., 2006). However, myogenic differentiation based on the EB protocol was inefficient. 
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To overcome these limitations, iPSCs were ectopically transduced with MYOD and 
PAX7 using lentivirus or adenovirus to efficiently induce the generation of skeletal 
muscle cells (Darabi et al., 2012; Tanaka et al., 2013; Tedesco et al., 2012). In addition, a 
monolayer culture for myogenic differentiation, the non-transgenic method was 
performed by the sequential treatment with the GSK3 inhibitor CHIR99021 and bFGF 
in serum-free medium (Borchin et al., 2013; Shelton et al., 2014). Previous study used 
GSK3inhibitor BIO, cAMP activator forskolin and bFGF to induce iPSCs to form EBs 
and further specifically differentiate into skeletal muscle cells (Xu et al., 2013). 
Furthermore, the low concentration (10
-8 
M) of retinol acids (RA) was shown to induce 
skeletal muscle cell generation from embryonic carcinoma cells (Edwards and McBurney, 
1983).  
 
Based on these previous studies, a directed differentiation protocol was established in this 
study to induce iPSCs into skeletal muscles with chemical molecules with high efficiency. 
To elucidate the muscle phenotype of XLMTM, iPSCs were generated from two 
XLMTM patients with MTM1 mutations (c.141_144 del AGAA and c.231+1G>A, 
respecitively). These iPSCs were further analyzed regarding their pluripotency.  
  
2 Materials and methods 
 
2.1 RT-PCR 
RNA was isolated and transcribed to cDNA according to the manufacturer’s instructions. 
The target genes were amplified with PCR, including PAX3, PAX7, MYOD, MYOGENIN 
and MYH7. The primers were:  
PAX3: for: TACAGGTCTGGTTTA GCAAC, rev: GATCTGACACAGCTTGTGGA; 
PAX7: for: ACCCCTGCCTAA CCACATC, rev: GCGGCAAAGAATCTTGGAGAC; 
MYOD: for: TGCCACAACGGACGACTTC, rev: TCTTGCGCTTGCACGCCTT; 
MYOGENIN: for: AGATGTGTCTGTGGCCTTC, rev: AGCTGGCTTCCTAGCATCAG;  





2.2 Immunofluorescence staining  
Directly differentiated skeletal muscle cells were fixed with 4% PFA and blocked with 1% 
BSA. Following permeabilization with 0.1% Triton X100, cells were stained with 
primary antibodies against -ACTININ (Sigma), Nebulin (Sigma), Desmin (Abcam) and 
MHC protein (R&D).  
 
2.3 iPSC generation  
Human fibroblasts derived from XLMTM patients with MTM1 mutations (c.141_144 del 
AGAA and c.231+1G>A) were transduced with STEMCCA virus containing the 
transcription factors OCT4, SOX2, KLF4 and c-MYC. iPSC colonies were picked 35-40 
days post transduction and cultivated as stable cell lines, iXLMTM1.1, 1.2, 1.3 and 
iXLMTM2.1, 2.2 and 2.4.  




In order to obtain skeletal muscle cells including progenitor myoblasts, nascent myotubes 
and beating myotubes, hiPSCs were seeded and cultivated into colonies with diameter of 
300-400 m in Essential 8 medium (Invitrogen) with pro-survival factors (Merck). The 
differentiation was initiated with supplementation of 4 M GSK3 inhibitor CHIR99021 
(Merck) for 4 days in DMEM/F-12 (Life technology). Thereafter, medium was changed 
to DMEMF/12 supplemented with 10 ng/ml bFGF (Peprotech), 20 g/ml forskolin 
(Sigma) and 10 ng/ml RA (Sigma) for another 14 days, which induce skeletal muscle 
progenitor’s generation. Skeletal muscle progenitors proliferated in the skeletal muscle 
growth medium (Promocell) for another 10-14 days. In addition, to enable myocyte 
fusion, skeletal muscle differentiation medium (Promocell) was used until day 45 to day 
60 (Figure 1A).  
 
Due to the modified differentiation protocol, the myocytes, nascent myotubes, fusing 
myotubes and beating myotubes were observed (Figure 1B). Furthermore, confirmation 
with fluorescence staining was performed and revealed that myocytes with single nuclei 
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and fused myotubes with multiple nuclei were α-ACTININ positive (Figure 2). Other 
striated muscle markers DESMIN and MHC were also highly expressed in these 
differentiated myocytes and myotubes (Figure 3B, C). The staining of specific marker 
for skeletal muscle cells demonstrated that they were NEBULIN-positive, indicating that 
these differentiated cells were skeletal muscle cells or their progenitors (Figure 3A). On 
transcript level, RT-PCR results showed high expression of skeletal muscle-specific 
markers MYOD, MYOGENIN and MYH7 as well as their progenitors-specific markers 
PAX3 and PAX7 (Figure 3D).  
 
The XLMTM patient-specific iPSCs (XLMTM-iPSCs) were reprogrammed from the 
fibroblasts derived from the biopsy of the donors who carry the MTM1 mutation 
(c.141_144 del AGAA and c.231+1G>A). Through characterization of pluripotency, the 
results illustrated that patient-specific iPSCs were pluripotent including positive alkaline 
phosphatase staining, high expression of pluripotency markers OC4, SOX2, NANOG, 
LIN28, SSEA4 and TRA1-60 and capacity of differentiation into derivatives of three 
germ layers in vitro and in vivo (Figure 4 and 5). 
 
Figure 1: Skeletal muscle differentiation from Ctr-iPSCs. Myotubes were differentiated using 
the protocol shown in A and bright field images were taken to show nascent myotubes at day 40 





Figure 2. Immunofluorescence staining of direct differentiated skeletal muscle cells.  
Sarcomere structure was shown in myocytes (A-C) at day 40 and myotubes at day 60 (D-E) 
stained with antibodies against -ACTININ. Scale bar: 50 m.  
 
Figure 3. Expression of skeletal muscle-related markers on protein and mRNA level. 
Sarcomere structure of myotubes at day 60 was shown stained with antibodies against other 
striated muscle markers including NEBULIN (A), DESMIN (B) and MHC (C). The generated 
myotubes highly expressed myogenic markers including PAX3, PAX7, MYH7, MYOD and 




Figure 4. “Proof of pluripotency”of XLMTM patient-specific iPSCs. The iPSCs lines 
(iXLM1.1, 1.2, 1.3 and iXLM2.1, 2.2 and 2.4) derived from two XLMTM patients with MTM1 
mutations c.141_144 del AGAA and c.231+G>A, respectively, were pluripotent, which was 
demonstrated by the alkaline phosphatase staining (A) and expression of pluripotent-related 




Figure 5. Spontaneous differentiation of XLMTM-iPSCs in vitro and in vivo. These iPSC 
lines were differentiated into cells or tissues of three germ layers as indicated by expression of 
endoderm marker AFP, mesoderm marker SMA and ectoderm marker -III-TUBULIN in vitro (A) 
and by teratoma formation with intestinal tissue (endoderm), cartilage (mesoderm) and 
neural-rosette structure (ectoderm) in vivo (B). Scale bar: 50 m. 
 
4 Discussion 
Skeletal muscle possesses the capacity to regenerate after trauma or disease because of 
the presence of skeletal-muscle resident stem cells (satellite cells), which are considered 
as a potential candidate for cell replacement therapy for muscle-related disease. However, 
there are some limitations to isolate the satellite cells in vitro due to their paucity and 
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difficulty to recruit healthy donors. The technique of reprogramming already committed 
adult cells into iPSCs enables a good approach to generate skeletal muscles in vitro and 
provides a powerful tool for research in human muscle development and muscle related 
disease.  
 
Here, we established a new modified skeletal muscle differentiation protocol with small 
chemical molecules. HiPSCs were exposed to CHIR99021 to induce the mesendoderm 
progenitor cells, which are committed to myoblasts after bFGF, forskolin and RA 
treatment. Myoblasts proliferate and differentiate to myocytes in skeletal muscle growth 
medium; myocytes then fuse with myocytes to form nascent myotubes and mature 
beating myotubes in skeletal muscle differentiation medium. This direct myogenic 
differentiation protocol generates skeletal muscles with advanced level of functional 
maturation, highlighted by the capability of spontaneous contraction. Comparing our 
differentiation protocol to previous reports, while the modified steps were performed in 
the absence of culture of embryoid bodies, sorting of progenitor cells and virus 
transduction, it remains laborious. In order to optimize and shorten the length of the 
differentiation protocol, myogenic-related genes and proteins would be analyzed at 
different stages of the differentiation process, revealing the optimal window to exchange 
medium and apply fresh supplements. Further functional analysis of derived skeletal 
muscle such as electrophysiological features would be useful for application of this 
system to dissect the molecular mechanism of muscle disorder. The skeletal muscle cells 
derived from XLMTM patient-specific iPSCs may model the disease phenotype and help 
to elucidate the molecular mechanism as a basis for the development of drug targets. 
Taken together, iPSCs from two XLMTM patients were successfully generated. The 
iPSCs were pluripotent and were differentiated into cells of three germ layers. To model 
the muscle phenotype in XLMTM, a myogenic protocol with chemical molecules was 
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